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SOMMARIO 
ERAP2 è una proteina associa al reticolo endolasmatico coinvolta nella 
presentazione di peptidi antigenici al complesso maggiore di 
istocompatibilità di classe I (MHC I). Si distinguono due differenti aplotipi 
del gene ERAP2, l’aplotipo A e l‘aplotipo B, caratterizzati dalla presenza di 
numerosi polimorfismi a singolo nucleotide (SNPs) in linkage disequilibrium 
tra loro. In particolare nell’aplotipo B la presenza di uno SNP a livello 
dell’introne 10 determina uno slittamento del sito classico di splicing 
generando un mRNA maturo che determina, in fase di traduzione, la 
prematura interruzione della sintesi proteica e la conseguente produzione 
di una proteina tronca. Al contrario, l’aplotipo A, genera un trascritto full-
lenght (ERAP2-FL) che codifica per la proteina canonica di ERAP2(Andres 
et al., 2010). Recentemente la presenza dell’aplotipo A e B di ERAP2, è 
stata correlata ad una diversa suscettibilità all’infezione da HIV-1. In 
particolare, è stata rilevata una maggiore frequenza dell’aplotipo A in una 
coorte di soggetti Italiani che, nonostante ripetute esposizioni al virus 
dell’HIV, tramite rapporti sessuali non protetti con partner sieropositivi (HIV 
exposed seronegative,HESN), non si infettano e non mostrano i segni 
clinici dell’AIDS (Cagliani et al., 2010). Alla luce di queste osservazioni, lo 
scopo del mio progetto di ricerca è stato quello di approfondire la 
correlazione esistente tra le varianti alleliche del gene ERAP2 e la naturale 
resistenza all’infezione da HIV-1 analizzando l’influenza che tali varianti 
esercitano nel meccanismo di presentazione antigenica. 
Metodi: ERAP2 è stato genotipizzato in una coorte di 104 HESN Spagnoli 
tossicodipendenti esposti al virus tramite  scambio di siringhe infette 
(IDU_HESN) e in 130 maschi bianchi sani utilizzati come controllo. 
Parallelamente, su 139 controlli sani (HC) suddivisi in funzione del genotipo 
di ERAP2 (AA, BB, AB) è stato condotto un saggio di infezione con HIV-1 
BaL R5 tropico e sono stati analizzati i seguenti parametri: 1) livelli di 
espressione di ERAP2-FL, ERAP2-SA ed ERAP2-Tot e di 84 geni coinvolti 
nella via di presentazione antigenica; 2) concentrazione dell’antigene virale 
p24; 3) intensità media di fluorescenza (MFI) dei complessi MHC di classe I 
su cellule CD45; 4) espressione delle proteine derivate dalla forma FL e SA 
di ERAP2 con Western Blot. Infine abbiamo analizzato la co-segregazione 
dell’aplotipo HLA-B57 con quello di ERAP2 in una coorte Italiana di HESN 
esposti al virus tramite rapporti eterosessuali non protetti. 
Risultati: I risultati ottenuti hanno confermato una maggior frequenza del 
genotipo A nei soggetti HESN Spagnoli rispetto al gruppo controllo a 
sostegno di un modello recessivo di protezione nei confronti di HIV-1. La 
meta analisi condotta su dati precedentemente pubblicati relativi ad una 
coorte di soggetti HESN italiani conferma l’associazione tra il genotipo omo 
A e la naturale resistenza all’infezione. Inoltre è stata individuata la co-
presenza dell’aplotipo HLA-B57 con quello omozigote per l’aplotipo A. I dati 
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ottenuti sui 139 controlli sani, dopo il saggio di infezione con HIV-BaL, 
mostrano un aumento statisticamente significativo dell’mRNA di ERAP2-
FL/TOT, di numerosi geni coinvolti nelle vie di presentazione antigenica e 
di molecole HLA-ABC sulla superficie cellulare leucocitaria in soggetti omo 
A.Questi risultati correlano con una riduzione statisticamente significativa 
dei livelli dell’antigene virale di HIV p24 in cellule periferiche mononucleate 
del sangue ma non in linfociti T CD4+. Infine la forma tronca della proteina 
non è stata rilevata in nessuno dei soggetti presi in esame.  
Conclusioni:  I risultati ottenuti suggeriscono che negli HESN il genotipo 
omoA di ERAP2 è correlato alla naturale esistenza all’infezione da HIV-1 
indipendentemente dalla via di esposizione al virus; che i livelli di 
espressione di ERAP2-FL ed SA differiscono in soggetti con diverso 
genotipo di ERAP2 e correlano con una diversa espressione sia di 
molecole HLA-ABC sulla superficie cellulare  che di geni implicati nel 
pathway di presentazione antigenica. Complessivamente, i risultati ottenuti 
lasciano presupporre che il genotipo A di ERAP 2 sia in grado di controllare 
la resistenza all’infezione da HIV-1 tramite il potenziamento dell’immunità 
cellula mediata. 
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ABSTRACT 
Background: The endoplasmic reticulum aminopeptidase type 2 (ERAP2) 
undergoes haplotype-specific alternative splicing which results in the 
production of either full-length (FL, from haplotype A ) or alternatively 
spliced (AS, from haplotype B) mRNA Resistance to HIV infection in a 
cohort of Italian sexually HIV-exposed seronegative individuals (HESN) is 
recently associated with a variant in ERAP2 that tags haplotype A. As the 
protein product of this gene trims peptides loaded on MHC class I, shaping 
the quality of viral peptides that are presented to CD8+ T cells, we further 
analysed its role in HIV-1-susceptibility. 
Methodology: ERAP2 was genotyped in a cohort of 104 Spanish HESN 
individuals exposed to HIV through injection drug use (IDU-HESN). In 
parallel PBMCs isolated from 139 healthy controls (HC) grouped according 
to their ERAP2 genotype were infected with HIV-1Ba-L and analysed for: 1) 
expression levels of mRNA specific for ERAP2 and for 84 genes involved in 
the antigen presentation pathway; 2) MHC class I MFI on CD45+ cells; 3) 
susceptibility to HIV-1 infection; 4) ERAP2 protein expression. Finally, we 
analyzed the co-segregation of HLA-B*57 with ERAP2 haplotype in a 
previously described cohort of Italian sexually-exposed HESN. 
Results: Genotype analysis in IDU-HESN mirrored the previous 
association between ERAP2 haplotype A and protection from HIV infection; 
meta-analysis with the Italian cohort yielded a p value of 7.6 x10-5.Co-
segregation analysis indicated that the HLA-B*57 allele is significantly more 
common among HESN homozygous for haplotype A (homo A) compared to 
non-homo A (p=0.01), suggesting genetic interaction.  
Data obtained in HC showed that following in vitro HIV infection the 
expression of mRNA for ERAP2-FL and a number of genes involved in 
antigen processing and presentation as well as of MHC class I on the 
surface of CD45+ cells are significantly increased in homo A cells; notably, 
homoA peripheral blood mononuclear cells, but not isolated CD4 cells, 
were less susceptible to HIV-1 infection. Only the expression of ERAP2-FL 
could be detected by western blot analyses. 
Conclusions: haplotype A of ERAP2 confers resistance to HIV infection 
independently of the route of exposure; such variation possibly affects MHC 
presentation and immune response. 
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CHAPTER 1. INTRODUCTION 
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1.1 Origin and history of the HIV/AIDS 
The human immunodeficiency virus (HIV) infection became evident in 1981 
by association of mortal cases of Pneumocystis cariini interstitial 
pneumonia among male homosexuals in Los Angeles who also 
characterized an intense state of immunodeficiency and complete loss of 
CD4+ T lymphocytes from their peripheral blood. 
The viral etiology in 1983, was identified for the first time in a new retrovirus 
particle by Fracoise Barré-Sinoussi and Luc Montignier (for which they won 
the Noble Prize in 2008) and confirmed in 1984 by the team of Robert C. 
Gallo to be the etiological agent of acquired immunodeficiency syndrome 
(AIDS) (Vicenzi at al., 2013). 
In 1984, HIV was found to be present in central Africa (Van de Perre P., 
1984. Piot Pet al., 1984). 
Later HIV seroposivity among two thirds of Nairobi prostitutes were 
described, demonstrating the presence of the epidemic in East Africa 
(Kreiss JK., et al., 1986). In 2012, the World Health Organization 
established that 2.5 million people became newly infected with HIV and that 
there were 34 million people living with the virus worldwide. It is estimated 
today that more than 34 million persons have been infected and, in large 
proportions, died of HIV infection or of AIDS-associated diseases. (Vicenzi 
at al., 2013). In fact, the state of profound immunodeficiency caused by HIV 
infection leads to the co-infection by other opportunistic pathogens, like 
Mycobacterium tuberculosis, hepatitis viruses, degeneration of central 
nervous system as well as the development of tumors mostly Kaposi’s 
Sarcoma and B-cell lymphoma.  
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1.2 HIV Virology 
1.2.1 HIV classification and structure 
HIV belongs to the viral Retroviridae family and the genus Lentivirus. HIV 
group M can be subdivided into 11 major clades (A1, A2, B, C, D, F1, F2, 
G, H, J and K). Circulating recombinant forms (CRF) also contribute to the 
extensive diversity of HIV subtypes. Clades A1, D and CRFs are 
predominant in Kenya, whereas clade B is prevalent in North America and 
Europe (Thomson MM et al., 2005).  
Two different types of HIV cause the same syndrome but differs for 
genome structure and antigenicity: HIV-1 is responsible for the AIDS 
syndrome in America, Europe and Central Africa, while HIV-2 is more 
prevalent in West Africa and in Asia (Clavel et al., 1986). 
HIV is an enveloped virus containing two identical positive sense single-
stranded RNA (ssRNA) genomes that colocalize in the icoshaedral core. 
The HIV genome encodes the envelope (Env) glycoproteins (gp120 and 
gp41), the internal structure core (Gag) proteins (p24, p9, p7 and p17), the 
enzymatic polymerase (Pol) proteins (reverse transcriptase (RT), integrase 
(IN) and protease (PR)) and the accessory proteins Vif, Vpr, Rev, Vpu, Tat 
and Nef (Turner et al., 1999).  
Nef is a virion–associate protein, originally considered “negative factor” for 
virus replication. Deletion of nef gene resulted in an asymptomatic infection 
in macaques that also showed a significant resistance to super-infection by 
wild-type SIV (Daniel et al., 1992). 
Vif is the acronym of “virion infectivity factor”. Indeed, Vif can be considered 
the prototype of viral antagonist of host-cell factors capable of restricting or 
preventing virus infection or replication. 
The accessory protein Vpu is present only in HIV-1. It functions like Nef and 
gp120 Env, contributes to the down-regulation of CD4+Tcells from the 
plasma membrane of infected cells (Dube et al., 2010). In addition, Vpu 
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counteracts a host cell protein, named BST-2 or Tetherin, which plays a 
role in the final step of the virus life cycle, i.e. budding and release of new 
progeny virions (Andrew A, et al., 2010).  
Like Tat the virion–associated protein Vpr was early identified as a 
transcriptional activator of HIV-1, particularly effective in non-dividing cells 
such as mature macrophages (Subbramanian et al., 1998). In addition, Vpr 
has been described as modulator of several additional steps in the virus life 
cycle, including reverse transcription. Vpr makes part of the pre-integration 
complex (PIC) that shuttles the viral genome to the cellular nucleus while 
undergoing conversion from RNA into DNA as result of the virion–
associated reverse transcriptase enzyme. At cellular level, Vpr induces cell 
cycle arrest in the G2/M phase, but also apoptosis.  
The virion-associated protein Vpx is present only in HIV-2, and in many SIV 
strains. Its expression facilitates virus replication in both T cells and 
macrophages. Recently Vpx was demonstrated to interact with host cellular 
target SAMHD1 that hydrolyzes the deoxynucleoside triphosphates 
required for the synthesis of HIV-1 and 2 DNA (Lahoussa H et al., 2012). 
 
1.2.2 HIV life cycle 
HIV enters target cells by binding of the viral envelope protein gp120 to 
CD4+ cells, which is expressed on cellular surface of different cell types. A 
conformational change allows gp120 to bind either of the coreceptors 
(CCR5 or CXCR4), depending on viral tropism (Greene WC et al., 2002). 
Transmission of viral infection generally occurs in a CCR5-dependent 
manner, as has been demonstrated by viral tropism determination of 
transmitted isolates. 
Following receptor binding, HIV enters in the cell by fusion between the 
viral envelope and in the cell membrane. Reverse transcription results in a 
single stranded complementary DNA copy, which is replicated to produce 
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the double stranded DNA proviral genome (Liu R et al., 1996). The process 
of reverse transcription is error-prone, leading to extensive diversity of 
progeny genomes. The proviral genome is transported to the nucleus and 
linear form of the double stranded DNA viral genome is inserted into the 
host chromosome. The integrated viral genome can remain latent for the 
lifetime of the host cell. However, binding of host factor to the 5’ long 
terminal repeat (LTR) region can lead to transcription of the viral genome. 
Translation of HIV transcripts produces polyproteins that are subsequently 
cleaved by viral and cellular proteases into individual viral proteins. 
Assembly occurs at the plasmamembrane and is followed by budding of 
progeny virions out of the host cell (Greene et al., 2002) (Fig.1.1)  
 
 
 
Figure 1.1 HIV life cycle (Engelman & Cherepanov Nature Reviews Microbiology 2012) 
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1.3 HIV pathogenesis  
1.3.1 HIV transmission 
HIV transmission is due to contact with infected body fluids. This may occur 
through sexual transmission (heterosexual or homosexual), parenteral 
transmission (injection drug use, receiving contaminated blood products), 
or vertical transmission (transmission of HIV from mother to child in utero or 
trough breast-feeding). Although transmission dynamics vary by population, 
heterosexual transmission accounts for the majority of incident HIV cases 
worldwide (Simon V et al., 2006). 
 
1.3.2 Disease progression 
The characteristic passage of HIV disease progression in the absence of 
ART is shown in Figure 1.2. After transmission, acute HIV infection typically 
lasts up to three months. Viremia peaks within a few weeks, and is followed 
by a sharp drop in viral load that coincides with the emergence of HIV-
specific CD8+ T cells. This low point in viral load is termed the viral set point 
(Helz et al., 2006) and is an indicator of HIV disease progression, such that 
individuals with low viral set points tend to exhibit slower progression to 
AIDS (Mellors et al., 1996). During acute infection, CD4+ T cell levels 
decline in the periphery but rebound as viral replication is contained. CD4+ 
T cells in the gut-associated lymphoid tissue (GALT) are extensively 
depleted early in infection, leading to prompt dysregulation of gut immunity. 
Acute infection is followed by a much longer chronic phase, in which there 
is excessive CD4+ T cell turnover and progressive decline of CD4+ T cells in 
the periphery. The onset of AIDS occurs when the CD4+ T cell count falls 
below 200 cells/µl of blood (Stevenson et al., 2003). At this point, the 
immunity system is unable to cope with infectious challenges, and the host 
eventually succumbs to opportunistic infections. 
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Figure 1.2 Clinical and immunologic events associated with disease progression in 
untreated HIV-1 infection 
 
1.4 HIV immunology 
1.4.1 Innate response to HIV infection 
The first line of defense against infection is the innate immune system and 
consists of innate immune cells, which are able to recognize and respond 
to infections quickly through the recognition of pathogens by pattern 
recognition receptors (PRR). These receptors include Toll-like receptors 
(TLRs), which recognize conserved motifs unique to microorganisms; in 
viral infections, they can detect double-stranded RNA (dsRNA) and single-
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stranded RNA (ssRNA), as well as certain viral proteins (Diebold et al., 
2004). It has been shown that HIV-1 ssRNA encodes for multiple TLR7/8 
ligands that can mediate direct activation of the immune system in vitro. 
Stimulation of TLR7/8 induces the production of several antiviral and 
immunomodulatory cytokines. In particular, interferon (IFN) production after 
TLR stimulation has been shown to be up regulated during acute infection 
with HIV-1 or SIV (Stacery et al., 2009). These early cytokines and the 
innate cells that produce them, such as dendritic cells (DCs), are pivotal in 
shaping the immune responses that develop in acute or early HIV-1 
infection. Recently, the cascade of cytokine production in the periphery has 
been thoroughly documented, showing an initial rapid increase and peaking 
of IFN-α production, followed by secondary tumor necrosis factor (TNF) α, 
and interleukin (IL) 18 secretion, and finally IL-10 and IFN- production, 
which was associated with the rise in virus-specific adaptive immune 
response (Norris et al., 2006). 
The comprehensive mechanism of IFN-α inhibition of HIV-1 is not well 
characterized, but in vivo elevation of IFN-stimulated genes (ISGs) has 
been observed in both gene expression proﬁling of HIV-1 and SIV infection. 
The in vitro inhibitory effects of IFNα on HIV-1 replication have been 
described in macrophages, monocytes, and humanized mouse models of 
HIV-1 infection (Lapenta et al., 1999). In addition to the activation of 
plasmacitoid dendritic cells (pDCs) through innate pattern recognition 
receptors, acute HIV-1 infection also results in the activation and expansion 
of natural killer cells (NK). In part, this activation of NK cells might be 
caused by high levels of proinﬂammatory cytokines secreted by DCs and 
monocytes, including IL-15 and IFNα. Initial studies demonstrated a 
signiﬁcant expansion of NK cell numbers in acute HIV-1 infection, in 
particular before the development of any detectable antibody responses 
(Alter et al., 2007). After this initial expansion of highly activated NK cells, 
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NK cells become increasingly impaired, with persisting viral replication and 
disease progression. 
 
1.4.2 HIV-specific B cells and antibodies 
The role of B cells in a protective immune response to HIV is contentious. 
Neutralizing antibodies are not correlated with control of viremia. However, 
non-human primate (NHP) studies have demonstrated passive protection of 
neutralizing monoclonal antibodies against virus challenge (Mascola JR et 
al., 2000). In addition, recent studies have identified several highly potent 
antibodies with broad neutralization coverage of HIV (Walker et al., 2011), 
leading support for vaccine strategies aimed at inducing neutralizing 
antibodies. 
Spontaneous activation of immunoglobulin G (IgG) secreting B cells and 
hypergammaglobulinemia were among the first immune dysfunctions 
reported in AIDS patients. A wide variety of B cell pathologies have been 
noted since then, recently reviewed in (Nicole et al., 2006)In the past year, 
B cells of HIV-infected patients were shown to have an abnormal 
distribution of various subsets: a decreased frequency of a CD27+B220− 
memory B subset and an increased frequency of CD20lo/−CD27hiCD38hi 
plasmablasts compared to uninfected controls. Tissue-like memory B cells, 
which have properties of exhausted cells (e.g. reduced proliferation and a 
truncated replication history) and the unusual phenotype 
CD27−CD20hiCD21lo, are shown to be increased in HIV-infected patients 
compared to uninfected controls. In addition, B cells of HIV-infected 
patients have an altered chemotactic capacity. Some changes in the B cell 
compartment, such as the proportions of immature/transitional cells, 
normalize to some extent during antiretroviral therapy although decreased 
frequencies of IgM memory B cells may persist. The majority of gp140-
labelled B cells are class-switched memory cells. In addition, although 
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plasmablasts are increased in HIV-infected patients, only a small fraction 
are observed to stain with gp140. Thus, it is possible that a large fraction of 
the plasmablasts that are increased in chronic HIV is not HIV-specific unlike 
the situation in acute responses to influenza vaccination (Nicole et al., 
2006). 
 
1.4.3 HIV-specific T cells 
HIV-specific CD8+ T cells arise within the first few weeks of infection as 
peak viremia declines, and correspond with the emergence of viral escape 
of mutation, implicating CD8+ T cells in initial control of viral replication. In 
line with this, CD8+ T cells isolated from HIV-infected individuals can inhibit 
viral replication in vitro (Saez-Ciriòn et al., 2007), and depletion of CD8+ T 
cells from SIV-infected macaques results in a loss of viral control and rapid 
disease progression (Jin X et al., 1999). The earliest CD8+ T cell responses 
are often specific for HIV Env and Nef proteins, although responses 
directed at Gag are associated with viral control later in infection (Turnbull 
et al., 2009). There are a large number of studies that convincingly 
demonstrate a requirement for HIV-specific CD8+ T cells in control of viral 
replication (Betts et al., 2006), but effective CD4+ T cell help is also required 
(Sun et al., 2003). 
HIV infects and progressively depletes CD4+ T cells, and HIV-specific 
memory cells are particularly susceptible to HIV-1 infection (Douek et al., 
2002). However, early administration of Anti-Retroviral Therapy (ART) can 
rescue strong HIV-specific CD4+ T cell responses. Robust HIV-specific 
CD4+ T cell responses are associated with better control of HIV viral 
replication (Potter et al., 2007) and HIV undergoes mutational escape from 
CD4+ T cell epitopes (Rychert et al., 2007). 
During chronic infection, exposure to HIV-specific T cells to persistent 
viremia leads to functional exhaustion. T cell exhaustion is characterized by 
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loss of proliferation capacity as well as polyfunction and cytotoxic ability, 
followed by apoptosis. Functional exhaustion is reflected by up-regulation 
of different inhibitory molecules on the cell surface, including programmed 
death 1 (PD-1), Cytotoxic T-Lymphocyte Antigen (CTLA)-4, lymphocyte 
activation gene (LAG)-3, T cell immunoglobulin domain and mucin domain 
(Tim)-3, 2B4 (CD244) and CD160 (Wherry 2011). PD-1 has been identified 
as a critical negative regulator in HIV infection (Zhang et al., 2007), and 
Tim-3 has been linked to elevated sensitivity to Treg-mediated suppression 
(Elahi et al., 2011). 
 
1.5 Models of Natural Protection 
1.5.1 HIV-exposed seronegative individuals (HESN) 
A characteristic feature of infectious diseases is that only a percentage of 
exposed individuals do become infected. Despite this awareness, during 
the first years after the explosion of the AIDS epidemics, little consideration 
was paid to the observation that parenteral exposure to HIV-1 does not 
consistently induce infection, and to the possibility that such putative non-
infectious exposure might be secondary to inheritable factors.  
Early epidemiologic studies from the UCLA Multicenter AIDS Cohort Study 
(MACS) (Inagawa et al., 1989) indicated that in a small percentage of 
homosexual men, frequent unprotected sexual contacts did not necessarily 
result in HIV sereoconversion. Interestingly, using peripheral blood 
leukocytes, HIV-specific T helper cell responses are shown to be present in 
these repeatedly exposed seronegative individuals, suggesting 
immunologic and/or genetic protection (Clerici et al., 1992). Shortly 
thereafter, other investigators reported the presence of a differential 
susceptibility to HIV infection in repeatedly-exposed female sex workers in 
Kenya (Plummer et al., 1993). Resistance to HIV infection was 
subsequently described in intravenous drug users, health care workers 
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accidentally exposed to HIV, homosexuals or heterosexual subjects that 
have unprotected sex with their seropositive partners, and hemophiliacs 
who had received HIV-contaminated anti-clotting factors. A particularly 
interesting cohort is represented by uninfected newborns of HIV-infected 
mothers. These infants are exclusive in that most of them are uninfected at 
birth (65-75%) despite having been continuously exposed to a HIV-
saturated environment during pregnancy; and are HIV seropositive, due to 
passively transferred maternal anti-HIV antibodies. During the first two 
decades after the discovery of this phenomenon, HIV-exposed uninfected 
individuals were referred to as exposed seronegatives (ESN), exposed 
uninfected (EU) or multiple exposed uninfected (MEU). Since the early 90s, 
numerous studies examined such cohorts of ESN in the attempt to define 
immunological and/or genetic correlates of protection to HIV infection, but 
none of the identified mechanism has so far been able to completely shed 
light on this phenomenon. Furthermore, efforts to compare results obtained 
in different cohorts of ESN and in different laboratories have been 
problematic for many reasons, including the lack of a codified and clear 
definition of who should be classified as ESN. 
In November 2009 the main investigators that had contributed to define the 
ESN/EU phenotype organized the first International Symposium on Natural 
Immunity to HIV which was held in Winnipeg, Canada, to definitely 
delineate the inclusion criteria of the ESN individuals and to compare the 
results of studies performed on different ESN cohorts. This first convention 
was followed by a second meeting that was held in Rockville, Maryland, in 
June 2010. At the second conference the decision was made to refer to 
these individuals as HESN, an acronym for HIV-Exposed Sero-Negatives. 
The results of these meetings were gathered in a supplementary number of 
the Journal of Infectious Diseases that summarizes the state of the art, as 
of the end of 2010 (JID Volume 202 Supplement 3 November 1, 2010) 
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While several HESN cohorts have been identified worldwide and are 
currently being studied by different groups, key information are still lacking. 
For instance, the relative contribution of genetic and immune factors to 
determine the phenomenon of resistance to HIV is not yet clarified. Notably, 
the possibility to study the early dynamic of this phenomenon is hindered by 
the definition of the resistance phenotype itself. In fact, the HESN status is 
assigned only after an individual has been able to efficaciously resist 
infection -typically over a period of years- despite multiple, frequent, and 
repeated documented exposures to the virus. Thus, researchers can only 
observe and compare the consequences of potentially important 
immunological changes that likely occurred years before the HESN status 
could be defined. Even so, if a genetic profile is at least partially 
responsible for this phenomenon it should be possible to identify this/these 
factor(s) at any time after exposure. Furthermore, once a putative 
protective variant gene is associated to the resistant phenotype, analyses 
can be easily performed using ex vivo infection assays on cells isolated 
from healthy controls carrying that specific mutation; it is therefore 
worthwhile to concentrate energy in this research field. 
Luckily, the integration of candidate gene approach with genome wide 
studies has allowed to identify a considerable number of genetic variants 
responsible for HIV-infection and the control over AIDS progression (Fig. 
1.3). 
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Figure1.3 Different cohorts that control HIV infection are used to assess the impact of 
hereditably factors on HIV-1 infection and/or progression. The main genetic correlates of 
protection to HIV infection so far identified by candidate gene approach are summarized 
 
1.5.2 Genetic correlates of protection 
1.5.2.1 Candidate-gene studies 
Candidate-gene studies imply an a priori knowledge of the gene function in 
HIV-1 pathogenesis (Shea et al., 2012). This approach selectively takes 
into consideration only variants in those genes known to be directly 
implicated in the HIV-1 life cycle or in the immune response to the virus, 
thus excluding still unidentified genetic factors potentially able to interfere 
with HIV-infection. Despite this apparent limit, most of the AIDS restriction 
genes identified so far with this approach have been subsequently 
confirmed by genome wide studies and essentially fall within the human 
leukocyte antigen (HLA) class I locus (An et al., 2010). The protective effect 
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of HLAB57, for example, has been confirmed in different studies in which 
the authors highlighted the ability of HLAB57-restricted cytotoxic T 
lymphocytes (CTL) to target multiple HIV peptides. The B5701 and the 
B5703 alleles (present mostly in Caucasians and Africans, respectively) 
exhibit a broad cross-reactivity against both common and rare variants of 
dominant gag epitopes, and have been associated with delayed 
progression of HIV disease (Makadzange et al., 2006; Boutwell et al., 
2009). Likewise, the expression of HLAB*27 has been shown to exert a 
protective effect by maintaining a high steadiness between the HLA B 
pocket and the arginine in position 2 of the gag peptide. In fact, mutations 
in this position lead to both instability of the B27-gag complex and faster 
progression to AIDS (Kelleher et al., 2007).  
Conversely, the B*35 allele was associated with a more rapid disease 
progression (Gao et al., 2001). Specifically, the B*35-Cw*04 haplotype is 
shown to be significantly associated with disease development in 
Caucasians but not in African-American (Carrington et al., 1999); 
suggesting that this variation exerts a negative influence on HIV 
pathogenesis (Huang et al., 2009). 
More recently, the HESN phenotype was associated with another gene 
involved in the antigen presentation pathway: the endoplasmic reticulum 
aminopeptidases 2 (ERAP2) (Cagliani et al., 2010). This enzyme trims 
peptides to optimal size for loading onto HLA I molecules and shapes the 
antigenic repertoire presented to CD8+ T lymphocytes. The haplotype 
network of ERAP2 is highly structured with two differentiated haplogroups: 
haplotype A and haplotype B. Haplotype A has a higher frequency in HESN 
and leads to the expression of a 960 amino acid full-length protein. 
Conversely, haplotype B, because of an alternative splicing, generates a 
truncated protein of 534 amino acids (Andres et al., 2010). 
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The association between NK activation and resistance to HIV infection has 
been established by diverse genetic studies. Jennes reported that African 
HESN sex workers are characterized by a higher frequency of inhibitory 
KIR genes in the absence of their associated HLA genes, and a higher rate 
of the AB KIR genotype, which includes more activating KIR. The evidence 
that NK activation exerts a defensive effect in HIV infection derives also 
from studies on the activating receptor allele KIR3DS1. Hence, Guerini 
observed an increase of homozygosis for this receptor in HESN compared 
to HIV-infected patients (Guerini et al., 2011), while Carrington reported 
that the presence of this allele is strongly protective in the presence of its 
presumed HLAB ligand(s) (Carrington et al., 2008). In addition, it was 
recently shown that copy number variations of activating and inhibitory KIR 
influence the peripheral expansion of protective KIR3DS1+ NK cells, which 
in turn may determine differences in HIV-1 control post infection (Pelak et 
al., 2011). Another key molecular family associated to the HESN phenotype 
is the one that includes chemokines and chemokine receptors. 
Contradictory results have been reported for: 1) polymorphisms in the 
regulatory region of the CCR5 gene 2) a genetic variant of CCR2 (CCR2-
64I), that is in strong linkage disequilibrium with a mutation in the CCR5 
regulatory region 3) an A-to-G substitution at position 801 within the 3' 
untranslated region of the SDF-1 chemokine gene; and 4) promoter 
polymorphisms responsible for increased levels of CC-chemokine 
production (RANTES, macrophages inflammatory protein (MIP)-1α, MIP-1β 
and MIP1αP) that can block R5-HIV-1 infection either by competition or by 
inducing receptor internalization (Biasin et al., 2012). 
More recently, analyses of the relationship between CCL3L1 copy number 
and susceptibility to HIV-1 infection showed that CCL3L1 levels are 
inversely correlated with CCR5 expression on CD4+ T lymphocytes 
(Gonzalez et al., 2005). Additional results performed in Human T-
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lymphotropic virus (HTLV)-2-infected individuals indicated that the median 
copy number of CCL3L1 and the CCL3L1/CCL3 mRNA ratios are 
increased in HESN and in Long Term Non Progressor (LTNP) compared to 
those seen in HIV-unexposed healthy controls. 
Notably, the APOBEC3 locus is present in the middle of chromosome 22 
and include 7 members (A, B, C, DE, F, G and H) which display different 
rate of anti-HIV activity. Apolipoprotein B mRNA-editing enzyme-catalytic 
polypeptide-like (A3G) (APOBEC3G) provokes G to A mutation on viral 
genome. Despite the fact that the HIV viral infectivity protein (VIF) can 
counteract A3G, a number of data suggest that A3G may play a role in 
altering the natural course of HIV infection.  
Among the other members of APOBEC family, attention has been recently 
focused on APOBEC3H. A case-control association analysis indicated that 
one of its haplotype, Hap I, is associated with protection from sexually 
transmitted HIV-1 infection. Hap I carries a protein-destabilizing variant as 
well as a residue conferring resistance to Vif-mediated degradation. These 
results suggest that lower protein stability might have been traded-off with a 
higher ability to circumvent Vif-mediated hijacking (Cagliani et al., 2011) 
Among host endocellular factors, modulating post-entry events of HIV 
replication, great attention has been focused on TRIM5α an antiviral factor 
that can restrict the replication of a wide range of retroviruses by interacting 
with the viral capsid. TRIM5α controls retroviruses in a species-specific 
manner; for example, TRIM5 α in the Rhesus Monkey completely blocks 
HIV-1 infection. As it was suggested that overexpression of human TRIM5α 
weakens HIV replication, polymorphisms in the TRIM5α gene were 
investigated as they could be associated with a higher anti HIV activity. 
One study found that the 136R (R136Q polymorphism) and the 43H (H43 
polymorphism) alleles do indeed correlate with in vitro resistance to HIV 
infection. Conversely, the 136Q allele was shown to be significantly more 
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frequent in HIV-infected individuals compared to HESN of Caucasian 
ethnicity, but this was not replicated in a second study (Speelmon et al., 
2006). Indeed, the same allele was observed to be more frequent in an 
African American HESN compared to HIV-infected patients (Nakajima et 
al., 2009). A different genetic background and diverse routes of exposure 
might justify the inconsistencies in these results. Single Nucleotide 
Polymorphisms (SNP) 43Y, was shown to be associated with reduced 
susceptibility to HIV-1 infection in Asians. This result nevertheless contrasts 
with in vitro evidences showing an accelerated disease progression in 
individuals who were homozygous for the 43Y genotype as compared to 
individuals who were heterozygous or homozygous for the 43H genotype. 
Other results indicated that the co-presence of the 136Q and of the -2GG 
alleles localized in the 5’ UTR of TRIM5. 
Candidate gene approaches have also been used to investigate 
polymorphisms in genes directly involved in the immune response to the 
virus. Thus, variants in genes codifying for cytokines or cytokines receptors 
as well as factors involved in signal transduction pathways have been taken 
into consideration. Cytokines are, indeed, crucial players in controlling the 
immune system and in fighting pathogens. Nevertheless, studies of 
polymorphisms in these effector molecule genes are often controversial, 
and the majority of these results indicate associations with susceptibility 
rather than resistance. More remarkable results stemmed from the study of 
Toll-Like receptors (TLR) a family of pattern-recognition receptors for 
bacteria and viruses. Interestingly, stimulation of PBMCs with agonists 
specific for TLR3 (poly I:C), TLR4 lipopolysaccharide (LPS), TLR7 
(imiquimod), and TLR7/8 (ssRNA40) resulted in higher cell responsiveness 
in HESN compared to healthy controls (Biasin et al., 2010). The ultimate 
mechanism responsible for this protection is to be better investigated but 
the activation of TLR pathway in HESN has recently been associated to an 
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increased expression of the full-length form of the adaptor protein MyD88, 
which acts as an intracellular negative regulator of this pathway. 
Furthermore, recent data obtained in two independent cohorts of HESN 
showed that a common TLR3 allele (rs3775291, Leu412Phe) confers 
immunologically-mediated protection from HIV-1 infection.  
 
1.5.3 Results from Genome-wide Association Studies (GWAS) 
Genome-wide association study (GWAS), a hypothesis-free approach, has 
led to the identification of new associations between genetic variants and 
infectious diseases, as well as to the validation of previously reported 
variants discovered by candidate-gene studies. This approach needs a very 
large sample size in order to have a sufficient statistical power to detect 
associations (the statistical significance at genome-wide level is a 
combined p value < 5x10-8) (Chapman et al., 2012). 
In the context of HIV-1 infection, different GWASs have been reported and 
associated with HIV-1 viral load and/or disease progression, but also with 
HIV-1 acquisition, replication and resistance. In 2007, Fellay investigated, 
in an European cohort, the presence of polymorphic variants that could 
correlate with viral load during the asymptomatic set-point period. Results 
demonstrated the presence of high levels of association of three different 
single nucleotide polymorphisms (SNPs) with a reduced viral load (Fellay et 
al., 2007; Shianna KV, Ge D et al.,). A whole-genome association study of 
major determinants for host control of HIV-1. One SNP, rs2395029, located 
in the HLA complex P5 (HPC5), is in high linkage disequilibrium (LD) with 
the HLA B*5701 allele, an allele identified by candidate gene approach as 
being protective toward progression to AIDS and associated with lower viral 
loads. The second SNP rs9264942, located upstream of the HLA-C gene 
and telomeric to the HPC5 gene, is correlated with differences in HLA-C 
expression levels. Finally, the third SNP, rs9261174 was located in a 
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regulatory 5’ region near the ZNRD1 gene and encodes a RNA polymerase 
I subunit, probably related to HIV-1 progression. In 2009, the same 
researchers published an extension of the first work. They first confirmed 
the strong association of the two main SNPs, rs2395029 and rs9264942, 
with variations in viral load and disease progression. In 2010, Pelak 
performed the first GWAs study to identify genetic correlates of protection 
against HIV-1 infection in a cohort of African American patients (Biasin e 
al., 2012). Results: 1)showed a strong association with an intronic SNP of 
HLA-B gene-rs2523608- tagging for HLA-B*5703; 2) confirmed the results 
obtained studying the European cohort for rs9264942; 3) did not confirm 
the presence of associations between the G allele of rs2395029 and 
protection, probably because of the low frequency of this allele in the 
African American population. Another goal of this research was to correlate 
significant SNPs to specific amino acidic positions within the HLA region, in 
particular, those involved in the interaction between viral peptides and HLA 
class I molecules. Results identified Arg97, Cys67, Gly62 and Glu63 in HLA-B; 
Ser77 in HLA-A; and Met304 in HLA-C as independent markers associated 
with HIV-1 control. These residues, with the exception of Met304 which is in 
the transmembrane domain of HLA-C, are located in the peptide binding 
groove of HLA class I, thus suggesting a role of the presentation of class I-
restricted epitopes in host control (Talenti et al., 2012). 
As summarized above GWASs have mostly highlighted the importance of 
the HLA region (mainly of HCP5/HLA-B*57) in controlling viral replication, in 
2010 nevertheless Limou presented a non-HLA-replicated association 
obtained by GWAS approach. Interestingly the results showed a strong 
association of rs2234358SNP with long-term non-progression. This variant 
maps within the CXCR6 gene and it seems to be correlated with its gene 
expression modulation. 
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As for resistance to HIV infection, results of only few GWASs have been 
published so far, but they did not succeeded in the identification of any SNP 
associable with the HESN phenotype. Petrovsky studied 848 HESN and 
531 HIV-1 seropositive individuals but despite the sufficient power of the 
study, no association is found. Lingappa performed a similar study in two 
cohorts of African HIV-1 sero-discordant heterosexual couples; again no 
SNPs are found to be associated with HIV-1 acquisition at genome-wide 
significance. More recently, GWAS performed in the attempt to identify 
additional genetic factors that could contribute to HIV-1 acquisitions, 
genotyping data of HIV-1 infected patients and uninfected control of the 
same ancestry from two European AIDS progression cohorts are 
compared. Results showed a strong association of the rs6996198SNP 
(chromosome 8) with a reduced risk of HIV-1 infection. This variant, which 
was more frequent in HESN than in HIV-infected patients, was previously 
associated with a higher transcriptional level of CYP7B1, a gene that plays 
a role in inflammation and in the synthesis of IgA. Another important GWAS 
study performed in two independent HESN cohort identified a correlation 
between resistant phenotype and a SNP minor allele rs1552896, in an 
intron of FREM1, an extracellular protein that can interact with many key 
factors for HIV-1 infection, establishment, and dissemination (Biasin et al., 
2013). 
Taken together, GWAS have confirmed the important role of HLA class I 
and CCR5 loci in the pathogenesis of HIV1 but these finding explain only a 
little portion of the inter-individual variability observed in HIV-1 control. 
Notably, the limited success of GWASs in studying HIV-1 
resistance/susceptibility is mostly due to the difficult in recruiting HESN 
cohorts sufficiently numerous for an adequately powered study. 
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1.5.4 Immune correlates of protection 
Innate immunity is likely to contribute to protection upon primary exposure 
to HIV in HESN before adaptive responses have developed.  
Accumulating functional evidence supports a role for NK activation in 
resistance to HIV infection (Montoya et al., 2006). Additionally, TLR 
stimulation of Peripheral Blood Mononuclear Cells (PBMCs) with TLR 
agonists resulted in higher cell responsiveness in HESN as demonstrated 
by elevated production of proinflammatory cytokines and chemokines 
(Biasin at al., 2010). 
Secreted factors have also been associated with reducing susceptibility to 
mucosal transmission of HIV. The β-chemokines macrophages 
inflammatory protein (MIP)-1α, MIP-1β and RANTES bind the HIV co-
receptor CCR5, thereby reducing HIV infection of target cells by 
outcompeting the virus for receptor usage. Peripheral production of β-
chemokines was associated with resistance to HIV-1 infection (Tomescu et 
al., 2011), and elevated salivary of β-chemokines were associated with oral 
sexual behavior in HESN MSM (Hasselrot et al., 2010). Elevated IL-22 has 
also been associated with resistance to infection in HESN, and is thought to 
act by induction of acute–phase serum amyloid A, which downregulates 
CCR5 expression on target cells (Missè et al., 2007). 
Multiple lines of evidences suggest that HIV-specific T cell responses are 
associated with resistance against HIV infection. HIV-specific T cells have 
been detected in PBMCs from commercial sex workers (CSW), men that 
have sex with men (MSM) discordant couples, occupationally exposed 
healthy care workers, injection drug users-HIV exposed seronegative (IDU-
HESN) and prenatally exposed infants. Both CD4+ and CD8+T cell 
responses have been linked to HIV infection in HESN. HIV-speciﬁc CTLs 
have been described in several different HESN cohorts and many authors 
claim that these cells make a fundamental contribution at modulating 
resistance to HIV infection. HIV-speciﬁc CTLs have been observed and 
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characterized in the Pumwani Kenyan cohort of sex workers both at 
systemic and mucosal levels; in injecting drug users; and in sexual partners 
of HIV-infected patients. These studies analyzed approximately 100 HESN 
individuals; HIV-speciﬁc CTLs were observed in the majority (>70%) of 
such HESN. The detection of HIV-speciﬁc CTLs in HESN individuals raises 
important scientiﬁc questions: only the successful infection of host cells, 
that is, infection resulting in at least one complete cycle of viral replication, 
allows the effective presentation of viral peptides within a binary complex 
with a human leukocyte antigen (HLA) class I molecule. The detection of 
HIV-speciﬁc CTLs in HESN individuals thus seems to indicate that HIV has 
managed to infect the host, but that its further propagation has been 
contained by immune mechanisms. The recent description of an alternative 
mechanism of processing and presentation by HLA class I molecules of 
exogenous antigens known as cross-priming could, nevertheless, explain 
the presence of CTLs in HESN individuals in the absence of actual 
infection. According to this mechanism, dendritic cells can process the virus 
and present it to CTL precursors in the absence of viral replication. If this 
were the case, the presence of HIV speciﬁc CTLs in HESN individuals 
would be the consequence, not necessarily of an infection, but of a different 
and presumably more efﬁcient processing pathway of HIV antigens within 
dendritic cells. 
In particular, HIV-specific CD8+ CTLs of the HESN individuals recognize 
HIV epitopes that are different from those recognized by cells of HIV-
infected patients 32 and Gag-stimulated CD8 T lymphocytes isolated from 
HESN individuals are characterized by higher levels of intracellular perforin 
and granzymes than those isolated from the HIV-infected partners (n ¼30 
HESN individuals studied) (Miyazawa et al., 2009, Kaul et al., 2001). 
HIV-specific IgA have been isolated from the female genital tract (FGT) of 
HESN CSW as well as uninfected partners of discordant couples (Devito et 
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al., 2002). However, similar antibodies were not detected in Gambian 
HESN CSW cohort and in Pumwany cohort there were HIV-specific IgA but 
no association was found between HIV-specific IgA and virus neutralization 
or shedding (Horton et al., 2009). 
1.6 Antigen processing and presentation 
Cytotoxic T lymphocytes (CD8+) monitor the surface of ‘professional’ and 
‘nonprofessional’ antigen presenting cells for the presence of viral 
infections. During infection, peptides from intracellular pathogens are 
generated and presented on the cell surface. This process is achieved 
through the major histocompatibility complex class I (MHC I) molecules. 
MHC I molecules bound to peptides (pMHC I) serve in fact as a flags for 
CD8+ T cells whose T cell antigen receptors (TCRs) recognize pMHC I and 
will eventually eliminate the infected or tumor cells. The formation and 
presentation of pMHC I complexes at the cell surface is a multistep process 
(Fig.1.4). First, endogenous proteins (viral proteins in case of virus-infected 
cells) are trimmed to peptides in the cytosol by the multicatalytic complex of 
the proteasome and several cytosolic peptidases. This step is followed by 
active translocation of peptides of 8 to 16 amino acids length across the 
endoplasmic reticulum (ER) membrane via proteins known as transporters 
associated with antigen processing (TAP1 and TAP2). While peptides of 8-
10 amino acids may directly fit in the MHC I binding groove, longer peptides 
need to undergo further trimming to produce mature N-termini 
(Brouwenstijn et al., 2001; Fruci et al., 2001; Lauvau et al., 1999). In mouse 
this step is catalyzed by ERAAP (endoplasmic reticulum aminopeptidase 
associated with antigen processing) (Serwold et al., 2002), while in human 
by two endoplasmic reticulum aminopeptidases, ERAP1 and ERAP2 (Saric 
et al., 2002; Saveanu et al., 2005; York et al., 2002). Finally, peptides are 
assembled with MHC I molecules and the pMHC I complex translocate to 
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the cell surface for the recognition by specific CD8+ T cells (Hammer et al., 
2007; Lehner and Cresswell, 1996). 
 
 
 
Figure 1.4 MHC I antigen processing and presentation. Cytosolic and nuclear proteins are 
degraded  by the proteasome. Peptides undergo further trimming by 
cytosolicaminopeptidases. The transporter for antigen processing (TAP) then translocates 
peptide into the lumen of the ER. The MHC I molecule folds with the assistance of the 
chaperones calnexin and calrecticulin, the adaptor molecule tapasin and the oxidoreductase 
ERp57. Protein disulfide isomerase (PDI) helps in formation of the disulfide bond in the a2 
domain of the MHC I molecule. ERAPs trim N-terminal extensions from antigenic precursor, 
thus resulting in the generation of final pMHC I complex that exit the ER and goes to the cell 
surface. (Fruci, et al., 2013)
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1.6.1 The MHC class I 
The MHC I genes encode polymorphic membrane glycoproteins that 
present peptides of foreign or self-origin to CD8+T cells. These molecules 
play critical roles in immune responses to viruses, MHC I proteins are 
encoded by three highly polymorphic genes, HLA-A, HLA-B and HLA-C, 
that are expressed in all eukaryotic cells (Little and Parham, 1999), and 
three less polymorphic genes, HLA-E, HLA-F and HLA-G that are 
expressed in a tissue-restricted fashion. 
In human, MHC I consist of two polypeptide chains, a heavy or α chain 
encoded in the MHC locus and a smaller non polymorphic light chain, ß2-
microglobulin, which is encoded elsewhere. 
The MHC-encoded polypeptide folds into three separate domains called α1, 
α2 and α3. ß2-microglobulin is non-covalently associated with the α3 
domain (Ohnishi, 1983). The α3 domain and ß2-microglobulin have a 
folded structure that closely resembles that of an immunoglobulin domain. 
The most remarkable feature of MHC I molecules is the structure of the 
folded α1 and α2 domains in which site of polymorphism are present. 
These two domains fold to make up a region bounded by a ß-pleated sheet 
on the bottom and two α helices on the sides. This groove, capable of 
binding via non-covalent interactions a small peptide of about 8-10 amino 
acids, is the peptide-binding site. The small peptide presented defines the 
antigenic epitope that can be recognize by CD8+ T-cell. MHC class I 
molecules are expressed by almost all nucleated cells, however, MHC 
class I molecules can also bind and present peptides from extracellular 
proteins to CD8+ T cells, a process known as cross-presentation (Cresswell 
et al., 2005). Once the TCR of CD8+ T cells recognizes peptide/MHC class I 
complexes at the cell surface, a T-cell signaling cascade is initiated and 
promotes the elimination of abnormal or virus-infected cells. 
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1.6.2 The ubiquitin-proteasome system 
Cytosolic protein degradation is mostly carried out by a large, multicatalytic 
protease complex (700 kDa) called the proteasome. The proteasome is 
found in the nucleus and cytosol of eukaryotic cells, where it is involved in 
non-lysosomal protein degradation of cytosolic proteins (Fehling et al., 
1994). The ubiquitinated proteins enter into the core of the proteasome 
where they are broken down into short peptides of 2 to 20 amino acids. The 
20S core of this complex has barrel shape made of four rings. The two 
outer rings are identical and each is composed of seven distinct α subunits. 
The two inner rings are also identical. Each contains seven different ß 
subunits, which surround a central chamber where proteolysis occurs. The 
activity is exerted by three of the ß subunits, namely ß1, ß2 and ß5. The 
20S core proteasome can associate with two regulatory complexes. 
Association with the 19S cap produces the 26S proteasome particle, which 
is able to degrade ubiquitin-conjugated proteins, whereas association with 
the P28 complex is thought to increase its catalytic activity (Tanaka and 
Kasahara, 1998). The major role of the proteasome is the degradation of 
intracellular proteins. The products of this degradation represent a major 
source of peptides for MHC I presentation. 
When cells are exposed to IFNγ the three catalytic subunits, ß1, ß2 and ß5 
are replaced by their IFNγ-inducible homolog LMP2 (ß1i), MECL1 (ß21) 
and LMP7 (ß5i), respectively. In vitro studies, performed with viral epitopes, 
showed that the proteasome equipped with LMP2, LMP7 and MECL1 is 
more efficient in processing a number of immunogenic peptides (Cerundolo 
et al., 1995). For this reason, it is called ‘immunoproteasome’ as opposed 
to the constitutively expressed standard proteasome. When tested in vitro 
on fluorogenic substrates the catalytic activity of the immunoproteasome is 
characterized by a reduced cleavage after acidic amino acids and an 
increase in the cleavage after hydrophobic and basic residues. As the latter 
residues are those most frequently binding to MHC I molecules, this 
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reinforced the notion that the immunoproteasome is more efficient than the 
standard proteasome for antigen presentation. It has been noted that 
changes in subunit composition sharpen the quantitative and qualitative 
ability of the proteasome to generate peptides, and thereby limit the 
production of self-peptides (Groettrup et al., 1996). Immunoproteasomes 
are constitutively expressed in immune tissues and expressed at much 
lower levels in other cell types where they can be induced by exposing cells 
to IFNγ or TNFa, cytokines released in the early stages of viral infections. 
The vast majority of the peptides produced during protein degradation by 
the cytosolic proteasome-ubiquitin system are consecutively hydrolyzed to 
single amino acids by multiple cytosolic peptidases. The small fraction of 
peptides surviving the aggressive cytosolic environment can be recruited 
for presentation by MHC I molecules (Kloetzel, et al., 2004).  
 
1.6.3 Peptide transport across membranes. 
The peptides generated in the cytoplasm are translocated into the ER 
through the Adenosine Tri-Phosphate (ATP)-dependent TAP1- TAP2 
heterodimer complex (Neefjes et al.,1993). Both TAP1 and TAP2 are 
spanning proteins with an ATP-binding cassette. The peptide transporters 
are selective for peptide length and the N- and C-terminal amino acids 
(Momburg and Hammerling, 1998). The translocation of peptides by TAP is 
tightly coupled to hydrolysis of ATP, so much so that TAP mutants unable 
to bind to ATP were also unable to bind, their peptide substrate. In an 
interesting example of functional convergent evolution, peptide binding and 
ATP hydrolysis are each targeted by several different viral immunoevasin 
proteins (Hansen et al., 2009). The higher the affinity of a peptide for TAP, 
the greater its likelihood of begin transported and the better the probability 
that it will be recognized by T cells during infection. In humans, a 
hydrophobic C-terminal is favored by TAP although basic residues can also 
29 
 
be accommodated. The peptides transported by TAP are generally 
between 8 and 16 residues in length, however, longer peptides can be 
transported, albeit with lower efficiency (Herget et al., 2011). 
 
1.6.4 The N-terminal trimming 
The peptides, after proteasome trimming, may have to be adapted to the 
strict MHC I-binding requirements by one or several N-terminal-trimming 
steps. An accepted model proposes that peptides of 15 or more residues 
are shortened by cytosolic tripeptidyl peptidase II. The cytosolic 
aminopeptidases including leucine aminopeptidase, leucine 
aminopeptidase, bleomycin hydrolase and puromicin-sensitive 
aminopeptidase, shown to contribute to the generation of individual 
epitopes while begin overall destructive and therefore for bulk antigen 
presentation. Nardilysin and thimet oligopeptidase have also been 
implicated in the generation of three defined CTL epitopes (Saunders et al., 
2011). However, such peptides can directly translocate into the ER lumen 
by TAP. In the ER, the NH2 terminus of these peptides is further trimmed 
by ER aminopeptidases, i.e., ERAP1 in mice and ERAP1 and ERAP2 in 
humans, to the proper length for binding to MHC class I molecules and 
presentation on the cell surface for recognition by NK cells and specific 
CD8+ T cells (Savenou et al., 2005). 
 
1.6.5 The peptide-loading complex 
The peptide loading complex (PLC) is a multisubunit structure in the ER 
containing TAP at its center assembled with MHC I molecules, ß2-
microglobulin, tapasin (tpn), calrecticulin, ERp57, and possibly protein 
disulfide isomerase (PDI) (Cresswell et al., 2005; Elliott and Williams, 
2005). Tpn, ERp57 and PDI are required for the stabilization of TAP and 
regulation of the redox state of a disulfide bound in the peptide-binding 
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groove of the MHC I heavy chain (Cabrera, 2007). Upon peptide loading, 
the PLC dissociates and the complex consisting of the MHC I and β2-
microglobulin is released and transported via the trans-Golgi to the cell 
surface to be exposed to CD8+cytotoxic T lymphocytes. Deficiency in 
components of the PLC can have dramatic consequences on the 
expression and quality of the pMHC I repertoire on the cell surface (Garbi 
et al., 2000). 
1.7 Endoplasmic Reticulum Aminopeptidases 
The endoplasmic reticulum (ER) aminopeptidase 1 (ERAP1) and the 
closely related ER aminopeptidase ERAP2 are zinc-metallopeptidases of 
the oxytocinase M1 subfamily, which share consensus zinc-binding motifs 
essential for their enzymatic activity (Hattori et al., 1999). The human 
ERAP1 and ERAP2 genes are located on chromosome 5q15 in the 
opposite orientation, likely to share regulatory elements. Human ERAP2 
has no analogues in rodents (e.g., mouse, rat, rabbit and guinea pig) and 
evolution studies suggest that it originates from a relatively recent 
duplication of ERAP1 (Andres et al., 2010). These enzymes are normally 
present in many tissues and are strongly induced after stimulation with type 
I and type II interferons (IFNs) (Servold et al., 2002; Tanioka et al., 2003) 
and tumor necrosis factor-alpha (TNF-a) (Forloni et al., 2010). ERAP 
enzymes trim aminoacid  residues from the NH2 terminus of polypeptides 
playing an important role in various biological processes. In the ER, ERAP1 
and ERAP2 cleave precursors to generate or destroy MHC class I binding 
peptides (Savenou et al., 2005; Servold et al., 2002). ERAP1 has also been 
involved in the regulation of innate immune and inflammatory responses by 
increasing the shedding of cytokine receptors (Cui X et al., 2002-2003). In 
addition to these immunological functions, ERAP1 and ERAP2 have been 
implicated in the regulation of angiogenesis and blood pressure (Sato et al., 
2004). According to these multifunctional properties, ERAP1 is also termed 
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endoplasmic reticulum aminopeptidase associated with antigen processing 
(ERAAP), adipocyte-derived leucine aminopeptidase (A-LAP), 
puromycininsensitive leucine-specific aminopeptidase (PILS-AP), or 
aminopeptidase regulating type I TNF receptor (TNFR1) shedding (ARTS-
1), whereas ERAP2 is known as leukocyte-derived arginine 
aminopeptidase (L-RAP). The terms ERAP1 and ERAP2, have been 
approved by the Human Genome Organization Nomenclature Committee. 
 
1.7.1 ERAP1 structure and its variants 
The ERAP1 human gene is located on the long arm of chromosome 5 
(5q15) and consists of 20 exons spanning about 47 kilo-bases (Hattori et 
al., 2001). The zinc-binding motif HEXXH is encoded in exon 6, while the 
essential glutamic acid (E) residue is encoded in exon 7. The GAMEN 
motif, which is shown to be important for the enzymatic action of gluzincin 
aminopeptidases, is also encoded in exon 6. Two major ERAP1 protein 
isoforms are generated depending on differences in exon 20: the longer 
isoform a (ERAP1-a) and the shorter isoform b (ERAP1-b). Recently, Kim 
et al. found that the isoform ERAP1-b is more abundant than that of the 
isoform ERAP1-a mRNA in various cell lines, and that the amount of the 
isoform ERAP1-b accounts for most of the cellular content of ERAP1 (Kim 
et al., 2011) 
These crystal structure of ERAP1 reveals an open conformation with a 
large internal cavity that can accommodate long peptide substrates and has 
features that explain ERAP1 broad specificity for antigenic peptide 
precursors. It has been hypothesized that binding of long peptide 
substrates in the catalytic and regulatory sites induces a conformational 
arrangement that leads to enzyme activation and efficient trimming (Kochan 
et al., 2011).  
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Potential effects on the biological functions of some of these variants can 
be inferred from the location in the ERAP1 structure: rs2287987 (M349V) is 
located in the active site and rs17482078 (R725Q) and rs27044 (Q730E) 
are exposed on the inner surface of the C-terminal cavity, which could 
affect substrate sequence or length specificity. Other polymorphisms, such 
as rs26653 (R127P), rs30187 (K528R), and rs10050860 (D575N) at 
domain junctions could indirectly affect either specificity or enzymatic 
activity by altering the conformational change between open and closed 
conformations. rs30187 and rs27044 have been repeatedly confirmed by 
nearly all population studies to confer strong susceptibility to disease. Both 
polymorphisms have been shown to cause a significant reduction in 
aminopeptidase activity towards a synthetic peptide substrate and several 
antigen precursor peptides (Evnouchiodou et al., 2011) 
 
1.7.2 ERAP2 structure and its variants 
The ERAP2 gene is located on chromosome 5q15, residing between 
ERAP1 and leucyl-cystinyl aminopeptidase (LNPEP) and contains 19 
exons, spanning about 45 kilo-bases. The GAMEN and HEXXH motifs are 
encoded in exon 6 while the essential E residue, located 19 amino acids 
downstream from the HEXXH motif, is encoded in exon 7. Exon 19 
contains the coding sequence for the last 47 aminoacids, stop codon and 
the 3′UTR region. A recent genetic analysis revealed that ERAP2 contains 
a variant that influences MHC class I antigen presentation. There are two 
different haplotypes of ERAP2 A and B, that correlate with the co-presence 
of different polymorphisms all in linkage disequilibrium between them. In 
particular, the single nucleotide polymorphism (SNP), Lysina 392 
Asparagina (K392N), determines the non-synonymous substitution of a 
polar basic residue, Lys (haplotype A), with neutral polar residue, Asp 
(haplotype B). In haplotype B the presence of the SNP rs2248374 (A to G), 
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located within the 5′ canonical splice site of exon 10, results in an 
alternatively spliced ERAP2 mRNA that contains a part of intron 10 that 
could be translated in a ERAP2-alternative spliced truncated protein of 
60kDa (ERAP2 AS) or degraded by non-sense mediated decay (NMD) 
(Andres et al., 2010). Heterozygous AG and homozygosity for the major A 
allele result in the expression of a 120KDa ERAP2-full length protein 
(ERAP2-FL), whereas homozygosity for the minor G allele results in the 
production of ERAP2-AS protein and reduced surface MHC class I 
expression in human lymphoblastoid cell lines (Andres et al., 2010) (Fig. 
1.5). 
 
Figure1.5 The genomic organization of the human chromosome 5q15 region containing 
ERAP1and ERAP2 is included at the top. The two haplotype specific ERAP2 spliced forms 
are shown for Haplotype A (in blue) and Haplotype B (in purple). The different alleles of 
rs2248374 are shown as a blue or purple base position, respectively. The red boxes 
represent the premature stop- codons in the Haplotype B mRNA (Andres et al.,2010) 
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The crystal structure of ERAP2 has been recently resolved and shown to 
have the same domain organization of ERAP1 (Birtley et al., 2012) with 
which a high homology (49% structural identity) is shared. The internal 
cavity, similar to that of ERAP1, extends from the catalytic site of the 
enzyme and can accommodate large precursor antigenic peptides. 
Moreover Birtley et al., demonstrate that ERAP2 is able to make a 
homodimer complex 
 
1.7.3 Trimming of antigenic peptides by ERAP1 
ERAP1 efficiently trims peptides of 9–16 amino acids, the length of 
peptides efficiently transported into the ER by TAP, but spares the longer 
ones (Chang et al., 2005). Of note, its activity is substantially reduced for 
peptides with proline at position 2 (X-P-Xn) (Servold et al., 2002), or for 
peptides with a size of 8 or 9 amino acids, the optimal length for binding to 
MHC class I molecules (Chang et al., 2005). ERAP1 shows a strong 
preference for peptides with large hydrophobic COOH-terminal residues 
(Chang et al., 2005). ERAP1 activity appears to be also affected by the 
nature of the internal residues of peptides. In particular, positions 2, 5 and 7 
(with position 1 defined as the N-terminal residue of the peptide) were 
found to be the most important for the peptide sensitivity to ERAP1 
degradation (Evnouchidou et al., 2008). Based on the analogies with TAP 
and MHC class I preferences, Chang et al. proposed the “molecular ruler” 
model for ERAP1 (Chang et al., 2005), that suggests its role in facilitating 
antigen processing and presentation by trimming precursors transported by 
TAP to MHC class I binding peptides. The substantial contribution of ER 
peptide trimming to MHC class I antigen processing and presentation has 
been confirmed in mice lacking ERAAP generated independently in four 
laboratories (Hammeret al., 2007). Although loss of ERAAP had a relatively 
modest effect on the cell surface expression of most MHC class I 
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molecules (a reduction of 20–40% for Kb and Db class I molecules) 
(Hammeret al., 2006). Immunization of ERAAP-/- mice with wild-type (wt) 
cells or vice versa, resulted in potent CD8+ T cell responses, suggesting 
that loss of ERAAP alters the peptide-MHC (pMHC) class I repertoire not 
only quantitatively but also qualitatively (Hammeret al., 2007). 
 
1.7.4 Trimming of antigenic peptides by ERAP2 
ERAP2 has been shown to cooperate with ERAP1 to trim a large variety of 
precursor peptides to generate mature epitopes for binding to MHC class I 
molecules (Savenou et al., 2005). ERAP2 is found to have distinct 
specificities for the N-terminal residue of the peptide substrates of ERAP1. 
In fact, the aminopeptidase 2 shows a strong preference for the basic 
residues Arg and Lys. ERAP2 crystallizes as a homodimer through head-
to-head interactions of the N-terminal domain that map an extended 
dimerization interface. Each monomer has an overall domain organization 
(domains I−IV) similar to that of the closed structure of ERAP1 [Protein 
Data Bank (PDB) entry 2YD0] with domain IV coming into the proximity of 
domain II, the catalytic site, and the S1 pocket (the latter defined as the 
specificity pocket accommodating the peptide side chain N-terminal to the 
scissile bond, according to the usual convention of defining peptidase 
specificity sites; subsequent specificity sites will be named S1′, S2′, etc.). 
This domain configuration generates an internal cavity that is of sufficient 
size to accommodate large peptides, similar to ERAP1. The shape and 
electrostatic potential distribution in that cavity, however, are distinct from 
the latter, suggesting that ERAP2 may apply distinct selective pressures in 
the antigenic peptide repertoire. Asp198 in ERAP2 is very important of N-
terminal specificity. Furthermore, same structure studies suggest that 
specificity differences between ERAP1 and ERAP2 may extend throughout 
the peptide-binding cavity. We map a common SNP of ERAP2 (rs2549782, 
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N392K), which has been linked with predisposition to disease, to a location 
adjacent to the active site of the enzyme. The ERAP2 homodimer in our 
structure is stabilized by an extended interface mediated by residues 
largely conserved in ERAP1 and may therefore constitute a useful model of 
the ERAP1−ERAP2 interaction.  
ERAP2 monomer is made of four structural domains (I−IV) forming a closed 
hollow structure. The N-terminal domain I (residues 54−271) exhibits a β-
sandwich structure. Domain II (residues 272−546) has a thermolysin α/β-
fold and contains the HExxHx18E zinc-binding motif as well as the GAMEN 
aminopeptidase motif. Domain III (residues 547−647) has a β-sandwich 
structure and acts as a link between domains II and IV. Domain IV 
(residues 648−960) is an all α-helical domain interacting closely with 
domain II, essentially capping the Zn (II) catalytic site (Fig. 1.6).  
 
 
Figure 1.6 Cartoon representations of known ERAP1/2 crystal structures. Domain I is 
shown in cyan, domain II in green, domain III in orange and IV in magenta. Note the 
repositioning of domain IV relative to domains I and II in the “open” versus the “closed” 
conformations (Efstratios Stratikos et al., 2013). 
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The contacts between domains II and IV define a large internal cavity, 
adjacent to the catalytic site, which has almost no access to the external 
solvent but exhibits numerous water molecules trapped inside it (Efstratios 
Stratikos et al., 2013). 
1.8 Alteration of ERAP function in human diseases 
ERAP1/2 are highly polymorphic with strong linkage disequilibrium evident 
across the gene. Recent GWAS have identified numerous ERAP1/2 single 
nucleotide polymorphisms (SNPs) strongly associated with different human 
diseases. Because of the role of these enzymes in MHC class I antigen 
presentation and in all other biological processes, it is conceivable that 
variations impairing the presentation of pathogen-derived peptides might 
lead to inadequate immune responses and development of disease. 
 
1.8.1 Hypertension 
By screening for 33 polymorphisms in the human ERAP1 gene, Yamamoto 
et al. identified the association of ERAP1 variant rs30187 (K528R) with 
essential hypertension and hypothesized that the R528 form of ERAP1 was 
less active than the K528 form, leading to hypertension due to reduced 
bradykinin formation and/or lower inactivation of angiotensin II (Yamamoto 
et al., 2002). This variant is shown to reduce by 60% the efficiency of 
ERAP1 to cleave angiotensin II to angiotensin III and by 70% to convert 
kallidin into bradykinin (Goto et al., 2006). The ERAP1 rs30187 variant is 
also found to determine the degree of regression of left ventricular 
hypertrophy during anti-hypertensive treatment in patients with essential 
hypertension (Hallberg et al., 2003).  
More recently, variants of ERAP1 and ERAP2 have been found to be 
associated with an increased risk of preeclampsia, a heritable pregnancy 
specific disorder characterized by new-onset hypertension and proteinuria 
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(Hill et al., 2011). Of note, ERAP2 expression is previously found altered in 
first trimester placentas of women prone to develop pre-clampsia (Founds 
et al., 2009). 
 
1.8.2 Bacterial and Viral infections 
ERAP1 plays an important role in immune response to viruses, either 
enhancing or reducing CD8+ T-cell responses to particular viral epitopes. 
ERAP1-deficient or wt mice infected with lymphocytic choriomeningitis virus 
(LCMV) showed profound differences in the frequency of CD8+ T cells 
specific for particular LCMV peptides (York et al., 2006). In wt mice the 
magnitude of T-cell responses to different LCMV epitopes followed a 
hierarchy of immunodominance that is markedly changed in the ERAP1-
deficient mice (York et al., 2006). 
Draenert et al. reported the first evidence that escape mutations arising in 
flanking regions of a human immunodeficiency virus (HIV) epitope alter 
antigen processing mediated by ERAP1 (Draenert et al., 2004). The 
authors showed that in HLA-B57+-HIV infected individuals, immune 
selection pressure leads to a mutation from alanine to proline at residue 
146 of HIV Gag protein immediately before the NH2 terminus of a dominant 
HLA-B57-restricted CTL epitope. This mutation was found to prevent the 
NH2-terminal cleavage by ERAP1, resulting in decreased CTL responses 
(Draenert et al., 2004). Of note, it was demonstrated that antigen 
processing shapes CTL response hierarchies, and that HIV evolution 
modifies cleavage patterns influencing proteasomal cleavage and, hence, 
the likelihood of CTL responses toward all epitopes (Tenzer et al., 2009). 
Interestingly, some variants in ERAP2 have been shown to confer 
resistance to HIV-1 infection possibly via the presentation of a distinctive 
peptide repertoire to CD8+ T cells (Cagliani et al., 2010).  
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Similarly, in cervical carcinoma induced by persistent infection and 
malignant transformation of the uterine cervical epithelium by human 
papillomavirus (HPV), increased cancer metastasis and decreased survival 
have been reported to be associated with several variants of ERAP1. In this 
case, down-regulation of ERAP1 may lead to the preferential loading and 
presentation of non-tumor-associated or non HPV-associated peptides, 
thereby yielding a less immunogenic phenotype and facilitating tumor 
growth and progression (Mehta et al., 2009).  
Recently, ERAP1 has been identified as a host target of human 
cytomegalovirus (HCMV) microRNA miR-US4–1, demonstrating a 
previously unknown miRNA-based immunoevasion strategy. Viral miR-
US4–1 interferes with MHC class I-mediated antigen presentation by 
targeting ERAP1, thereby influencing the production of many HCMV-
derived antigenic peptides during viral infection, which results in 
immunoevasion of the recognition of viral antigen by CD8+ T cells during 
the host immune response (Kim et al., 2011). 
 
1.8.4 Autoimmune diseases  
Recent genome-wide association studies (GWAS) have proven the 
importance of ERAP1 and ERAP2 genes in conferring susceptibility of 
individuals to different autoimmune diseases and their linkage with 
particular MHC class I alleles (Fierabracci et al., 2011).  
The association between ankylosing spondylitis (AS) and ERAP1 variants 
has been founded in different population like Caucasian and Mongolian 
persons (Maksymowych et al., 2009; Davidsonet al., 2009; Choi et al., 
2010; Harvey et al., 2009). More recently, the association with the variant 
rs30187 has been exclusively found in a cohort of HLA-B27-positive AS 
patients (Evans et al., 2011). Moreover, this functional polymorphism 
confers susceptibility to MS in Italian populations (Guerini et al., 2012). Of 
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note, the disease-associated ERAP1 variant rs30187 (K528) had faster rate 
of trimming of peptide precursors than protective ERAP1 variant (Evans et 
al., 2011). Taken together, these findings support a model in which 
aberrant peptide trimming by ERAP1 and, as consequence, impaired 
peptide presentation by HLA-B27 are involved in the AS pathogenesis 
(Evans et al., 2011).  
A recent meta-analysis of six Crohn’s disease GWAS identified ERAP2 as 
one of the most interesting candidate genes (Franke et al., 2010).  
 
1.8.5 Cancer 
ERAP1 and ERAP2 are expressed in all tumor cell lines examined 
(melanomas, leukemia-lymphomas and carcinomas of breast, colon, lung, 
chorion, skin, prostate, cervix, kidney and bladder) at highly variable levels 
and independently from each other (Fruci et al., 2006). MHC class I surface 
expression is significantly correlated with ERAP1, but not with ERAP2, 
suggesting that ERAP1 has a dominant role in the generation of MHC class 
I epitopes (Fruci et al., 2006). In a subsequent study, ERAP1 and ERAP2 
are investigated in a large panel of surgically removed normal and 
neoplastic tissues. In approximately 150 neoplastic lesions, the expression 
of either or both enzymes was lost, acquired or retained as compared to the 
normal counterparts, depending on the tumor histotype (Fruci et al., 2008). 
Down-regulation of ERAP1 and/or ERAP2 expression is mainly detected in 
ovary, breast and lung carcinomas, whereas an up-regulation of these 
enzymes was observed in colon and thyroid carcinomas (Fruci et al., 2008).  
Of note, ERAP1 and MHC class I are coordinately expressed in normal 
and, to a lesser extent, neoplastic lesions. As expected, the altered 
expression of ERAPs results in abnormal cell surface expression of MHC 
class I molecules in tumor cell lines (Fruci et al., 2006). In the most 
aggressive type of neuroblastoma cells, ERAP1, ERAP2 as well as MHC 
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class I molecules are expressed at very low levels as consequence of a 
poor constitutive NF-kB nuclear activity (Forloni et al., 2007) 
In a recent study, heterogeneous expression of ERAP1 and ERAP2, 
ranging from high to very low levels, is detected in 28 melanoma cell lines 
as compared to primary melanocytes (Kamphausen et al., 2010). In most 
cases, expression of these genes is enhanced by IFN-.treatment, 
suggesting that it is under control of regulatory mechanisms and that only in 
rare cases to abnormalities in their sequences (Kamphausen et al., 2010).  
Expression of ERAP1 has been detected in 64% of endometrial carcinomas 
and correlated with CA-125 levels, suggesting a role of this enzyme in 
endometrial cancer cell growth and differentiation (Kazeto et al., 2003; 
Watanabe et al., 2003; Shibata et al., 2005). The authors also showed that 
ERAP1 suppresses angiogenesis and endothelial cell migration in human 
endometrial carcinoma by regulating the angiotensin II concentration 
(Watanabe et al., 2003).  
A recent study demonstrated that interfering with ERAP1 expression 
ultimately leads to tumor rejection in syngeneic animals by boosting NK 
cell, and subsequently T cell-mediated cytolysis. This rejection was mainly 
due to NK cell response and depends on the MHC class I peptides 
presented by ERAP1-silenced tumor cells, because replacement of the 
endogenous peptides with high-affinity peptides was sufficient to restore an 
NK protective effect of MHC class I through the NK inhibitory receptor 
Ly49C/I (Cifaldi et al., 2011).  
Of note, Wang et al., showed that there is a strong correlation between 
ERAP1 and tumor suppressor factor p53. In fact, p53 could directly activate 
ERAP1 influencing in this way the expression on cell surface of MHC class 
I molecules (Wang et al., 2013). 
 
42 
 
1.8.6 Cytokine Receptor Shedding 
In addition to antigen processing, ERAP1 has been shown to promote the 
cleavage of several cytokine cell surface receptors (Cui X,et al., 2012). Cui 
et al. demonstrated that ERAP1 binds to the extracellular domain of the 
TNFR1, facilitating TNFR1 shedding through the formation of a 
TNFR1/ERAP1 complex. The authors showed that overexpression of 
ERAP1 produces soluble TNFR1 that competes with cell-surface TNF 
receptors, thereby attenuating TNFα bioactivity when the levels are 
elevated, and reconstituting TNFα when the levels have declined (Cui X et 
al., 2003). However, several evidences demonstrated that ERAP1 is not 
required to be catalytically active for this function. Coimmunoprecipitation 
experiments revealed that ERAP1 could bind to, but not cleave TNFR1. 
Moreover, ERAP1 does not possess endopeptidase activity and 
overexpression of ERAP1 catalytic mutants results in an increased TNFR1 
shedding. Thus, ERAP1 does not directly catalyze TNFR1 shedding, but 
may instead promote the activity of a TNFR1 sheddase. Subsequently, the 
same authors showed that ERAP1 modulates the proteolytic cleavage of 
two other cytokine receptors, the type I IL-6 cytokine receptor (IL-6Rα) (Cui 
X et al., 2012) and the type II IL-1 decoy receptor (IL-1RII) (Cui X et al., 
2003). Based on these functions, ERAP1 has been proposed to play an 
important role in regulating innate and inflammatory immune responses by 
increasing the shedding of these cytokine receptors. 
1.9 Non immunological function 
ERAP1 and ERAP2 are thought to play a role in the regulation of blood 
pressure through their involvement in the renin-angiotensin system. In vitro 
studies using Chinese Hamster Ovary cells demonstrated that ERAP1 
efficiently cleaves angiotensin II to angiotensin III and IV (Hattori 2000), 
while ERAP2 cleaves angiotensin III to angiotensin IV (Tanioka et al., 
2003). In the same system, both enzymes are shown to convert kallidin to 
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bradykinin (Tanioka et al., 2003) In addition, ERAP1 has been reported to 
control post-natal neo-angiogenesis, a physiological process involving the 
growth of new blood vessels from pre-existing microvessels, by regulating 
the proliferation and migration of endothelial cells (EC) (Miyashita et al., 
2000). Functional studies revealed that ERAP1 is expressed in ECs during 
differentiation in vitro and at the site of angiogenesis in vivo upon 
stimulation with vascular endothelial growth factor (VEGF) (Miyashita et al., 
2000). Suppression of ERAP1 expression in ECs inhibited VEGF-
stimulated proliferation, migration, vessel network formation in vitro, and 
angiogenesis in vivo (Miyashita et al., 2000). The authors also 
demonstrated that ERAP1 regulates VEGF stimulated G1/S transition 
during EC proliferation by binding to phosphatidylinositol-dependent kinase 
1 (PDK1). Formation of the ERAP1-PDK1-S6 kinase complex resulted in 
activation of cyclin-dependent kinase (CDK) 4/6 by phosphorylated S6K 
that promotes G1/S-phase transition leading to EC proliferation (Yamazak 
et al., 2004). It was also demonstrated that ERAP1 controls the spreading 
of ECs by activating endothelial integrins and focal adhesion kinase (Akada 
et al., 2002), increasing EC adhesion to the extracellular matrix via RhoA 
activation (Suzuki et al., 2007). More recently, ERAP1 has also been 
shown to bind pigpen, a nuclear-coiled body component protein involved in 
angiogenesis (Yoshidaet al., 2010; Abe et al., 2006). However, how pigpen 
interacts with ERAP1 to promote angiogenesis and whether pigpen is a 
substrate for ERAP1 remains to be established. 
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ERAP1 and ERAP2 play an important role in immune response to viruses, 
either enhancing or reducing CD8+ T-cell responses to particular viral 
epitopes. RNA interference experiments have produced contrasting results 
concerning the effect of ERAP1 and ERAP2 on MHC class I molecule 
expression and peptide presentation (Sovenau et al., 2005; York et al., 
2002), suggesting that factors such as peptide sequence, cell-type and 
MHC class I alleles may determine whether the two aminopeptidases 
enhance or inhibit antigen presentation. 
In addition, haplotype variations have already been associated with 
different autoimmune diseases and tumoral forms (Fruci et al., 2013). 
Moreover, haplotype A of ERAP2 was shown to have a higher frequency in 
a cohort of seronegative subjects repeatedly exposed to HIV trough 
unprotected heterosexual intercourses suggesting that ERAP2 haplotypes 
could play a role in resistance to HIV infection (Cagliani et al., 2010).  
In this context, the present study aims at confirming the correlation between 
ERAP2 haplotypes and susceptibility to HIV-1 by verifying whether diverse 
ERAP2 alleles differently modulate antigen processing and presentation. 
 
 
 
 
 
 
 
  
CHAPTER 3. MATERIAL AND 
METHODS 
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3.1 Cohorts enrolled in the study  
Two different HESN cohorts were enrolled in this study. The first one 
included 69 Italian HESN subjects exposed to the virus through 
unprotected heterosexual intercourses. Inclusion criteria were a history of 
multiple unprotected sexual episodes for more than 4 years at the time of 
the enrollment, with at least three episodes of at-risk intercourse within 4 
months prior to study entry and an average of 30 (range 18 to 100) 
reported unprotected sexual contacts per year. 218 healthy Italian donors 
were used as controls.  
The second cohort included 104 white males exposed to HIV-1 infection by 
injection drug use (IDU) from a Spanish cohort (Valme Hospital, Sevilla) 
who have been sharing infected needles for a period longer than 3 months 
and with a concurrent hepatitis C infection (HCV). A group of 130 HIV-1 
and HCV-seronegative healthy white male blood donors from the Jaen 
Hospital was used as control. 
The study was designed and performed according to the Helsinki 
declaration and was approved by the ethics committee of the participating 
units. All participants provided written informed consent to participate in this 
study. 
Similarly, informed consent was obtained from 139 HIV-1 seronegative 
Italian healthy controls who gave their blood to perform functional analyses. 
Whole blood was collected from all participants, and DNA was extracted by 
phenol chloroform method (Promega, Madison, Wisconsin, USA). 
 
3.1.2 Genotyping 
Genomic DNA was used as template for PCR amplification using TaqMan 
probes specifically designed to perform a SNP genotyping assay for 
rs2549782 (G/T) (TaqMan SNP Genotyping Assay; Applied Biosystems, 
Foster City, California, USA) and using the allelic discrimination real-time 
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PCR method. The polymorphic 32 base pair deletion at the CCR5 locus is 
typed by PCR using specific primers (forward: 5 
TGGTGGCTGTGTTTGCGTCT-3; reverse: 5-
ATGACAAGCAGCGGCAGGAC-3). The PCR products is 
electrophoretically separated on 3% agarose gels. 
3.2 HLA typing 
Genomic DNA was isolated from peripheral blood by phenol-chloroform 
extraction using standard procedures. HLA typing of class-I HLA-B locus 
was performed by the Sequence Specific Primer amplification (SSP-PCR) 
method using Histo-Type DNA plates (BAG health care, Formedic s.r.l., 
Milano, Italy) according to the manufacturer's instructions. Detection of the 
alleles recognized by the specific primers was possible after amplification in 
a GeneAmp PCR 9700 thermocycler (Applied Biosystem, Foster City, CA 
U.S.A.) and gel electrophoresis on 2% agarose gel. 
3.3 Isolation of PBMCs 
Peripheral blood mononuclear cells (PBMCs) were separated by whole 
blood on lymphocyte separation medium (Lympholyte-H, Cederlane 
Laboratories, Burlington, NC, USA). Briefly, whole blood was centrifuged 
for 25 minutes at 2300 RPM, without brake, on a Ficoll discontinuous 
density gradient  
After the centrifugation step, the blood sample was separated showing the 
following layers from top to bottom plasma and platelets, the PBMCs band 
situated at plasma/Ficoll interface, Ficoll and red blood cells, covered by a 
granulocyte layer.  
The PBMCs layer were carefully removed from the tube and transferred to 
a new conical tube. The PBMCs were then washed with phosphate 
buffered saline (PBS) and cell number and cellular vitality were determined. 
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3.4 CD4 T lymphocytes magnetic separation 
CD4+ T lymphocytes were separated from PBMCs by direct magnetic 
labelling using the CD4-microbeads (Miltenyi Biotech, Bergisch Gladbach, 
Germany), according to manufacturer’s protocol. Briefly, the CD4+ cells are 
magnetically labeled with CD4MicroBeads. Then, the cell suspension is 
loaded onto a MACS® Column, which is placed in the magnetic field of a 
MACS Separator. The magnetically labeled CD4+ cells are retained within 
the column. The unlabeled cells run through; this cell fraction is thus 
depleted of CD4+ cells. After removing the column from the magnetic field, 
the magnetically retained CD4+ cells can be eluted as the positively 
selected cell fraction.  
3.5 Cell cultures 
PBMCs were cultured at 37°C and 5% CO2 in RPMI 1640 supplemented 
with 10% AB human serum and stimulated with different concentrations of 
IFNγ (12 ng/ml and 60 ng/ml) for 3h; 24h, 48h and 72h.  
Moreover, 1x106 PBMCs were cultured for 20h with 300 µg/mL of 
gentamicin to block NMD complex.  
3.6 HIV infections assay 
PBMC and CD4+ T cells (10×106 cells/mL) were cultured for 2 days at 37°C 
and 5% CO2 in RPMI 1640 containing FBS (20%), phytohemagglutinin 
(PHA) (7.5 μg/mL), and interleukin (IL)—2 (15 ng/mL). After viability 
assessment, 2.5×106 cells were resuspended in medium containing 1 ng of 
HIV-1Ba-L p24 viral input/106 PBMCs and incubated for 3 h at 37°C. Cells 
were then washed and resuspended in 3 mL of complete medium with IL-2 
(15 ng/mL). Cells were plated in 24-well tissue culture plates and incubated 
at 37°C and 5% CO2. After 5 days supernatants were collected for p24 
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antigen ELISA and MHC I analyses, while PBMCs and CD4+ T cells were 
collected at 3 days and used for RNA extraction.  
3.7 p24 ELISA 
As a measure of HIV infection, p24 concentration was assayed using the 
Alliance HIV-1 p24 Antigen kit (Perkin Elmer, Boston, USA) following 
manufacturer’s instructions. Analyses were performed on culture 
supernatants from both PBMCs and CD4+ T cells collected 5 days post 
infection analyses. Briefly, cell culture samples are added directly to the 
monoclonal antibody-coated microplate wells. The captured antigen is 
complexed with biotinylated polyclonal antibody to HIV-1 p24, followed by a 
streptavidin-HRP (horseradish peroxidase) conjugate. The resulting 
complex is detected by incubation with ortho- phenylenediamine-HCl (OPD) 
which produces a yellow color that is directly proportional to the amount of 
HIV-1 p24 captured. The absorbance of each microplate well is determined 
using a microplate reader and calibrated against the absorbance of an HIV-
1 p24 antigen standard curve. Samples with absorbance values equal to or 
greater than the cutoff factor were considered initially reactive, but were 
retested in duplicate to determine whether the reactivity is reproducible. 
3.8 RNA extraction  
RNA was extracted from basal and cultured PBMCs and CD4+ T 
lymphocytes by using the acid guanidium thiocyanate–phenol–chloroform 
method. RNAzol B reagent (TEL-TEST, Inc., Duotech, Milan, Italy), a 
monophase solution containing phenol and guanidine thiocyanate, was 
used.  
Cells were lysed in RNAzol B and the lysate was separated into aqueous 
and organic phase by the addition of chloroform (20% of RNAzol B initial 
volume used). 
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Samples were centrifuged (at 12,000g 15 minutes at 4°C) to efficiently 
remove DNA and proteins from the aqueous phase containing RNA. The 
undegraded, pure RNA was obtained from the aqueous phase by  
isopropanol precipitation and washing with 75% ethanol. RNA quantity and 
purity was analyzed at Nanodrop 2000 Spectrophotometer (Thermo 
Scientific) 
3.9 DNAse treatment and retrotranscription  
The RNA was dissolved in RNase-free water, and purified from genomic 
DNA with TURBO DNAse (Applied Biosystems/Ambion, Austin, TX), a 
genetically engineered form of bovine DNase I with greater catalytic 
efficiency than conventional DNase I at higher salt concentrations and 
lower DNA concentrations. A reaction mixture, containing 1µg of RNA, 
Turbo DNasi 1U and TURBO DNasi Buffer, was incubated 30 minutes at 37 
°C. Then DNase was inactivated by DNase inactivation reagent (Applied 
Biosystems/Ambion), that binds and removes the divalent cations from 
DNase.1 µg of RNA is reverse transcribed into first-strand cDNA in a 20-µl 
final volume. A reaction mixture, containing 1 µM random hexanucleotide 
primers, 1 µM oligo dT and the RNA, was heated at 70 °C for 5 minutes to 
melt secondary structure within the template. The mixture was immediately 
cooled on ice to prevent secondary structures from reforming. A dNTPs 
mix, 200 U Moloney murine leukemia virus reverse transcriptase (M-MLV 
RT), 20 U Recombinant RNasi inhibitor and M-MLV 5X reaction buffer were 
added (Promega). The reaction mix was incubated 60 minutes at 42 °C and 
then heated 5 minutes at 95 °C to inactivate the RT. 
3.10 Real Time PCR 
cDNA quantification for ERAP2-FL, ERAP2-AS, TAP1, IFNg, and GAPDH 
was performed by real-time PCR (DNA Engine Opticon 2; MJ Research, 
Ramsey, MN). We also designed primers that do not discriminate ERAP2-
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FL from ERAP2-AS, to quantify the total content of ERAP2 (ERAP2-TOT). 
Reactions were performed using a SYBR Green PCR mix (Finnzymes, 
Espoo, Finland). SYBR green is a fluorogenic minor groove binding dye 
that exhibits little fluorescence when in solution but emits a strong 
fluorescent signal upon binding to double-stranded DNA. Reactions were 
performed according with the following thermal profile: an initial 
denaturation (95 °C ,15 minutes) followed by 40 cycles of 15 sec at 95 °C 
(denaturation) and 1 min at 62 °C (annealing) and 20 seconds at 72 °C 
(extension). By recording the amount of fluorescence emission at each 
cycle, the PCR reaction was monitored during exponential phase, where 
the first significant increase in the amount of PCR product correlates to the 
initial amount of target template. The higher the starting copy number of the 
nucleic acid target, the sooner a significant increase in fluorescence is 
observed. Melting point or dissociation curve analysis for amplicon 
identification, was performed. 
The threshold line is the level of the detection or the point at which a 
reaction the reaction reaches a fluorescent intensity above background (the 
mean of fluorescence values detected from to third to tenth cycle, when 
target amplification is no appreciable yet). The threshold is set placed 
above baseline activity and in the exponential increase phase of the 
amplification for the most accurate reading. The parameter Ct (Threshold 
Cycle) is defined as the fractional cycle number at which the fluorescence 
passes the fixed threshold. The higher the initial amount of genomic DNA, 
the sooner accumulated product is detected in the PCR process, and the 
lower the Ct value. A Ct value of 40 or higher means no amplification and 
this value is not included in the calculations.  
Results were expressed as ΔΔCt and presented as ratios between the 
target gene and the GAPDH housekeeping mRNA. All the samples were 
analyzed in triplicate. All primers are summarize in Table 3.1.
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Table 3.1. List of primers used to assess the expression of genes TAP1, IFNγ, ERAP-FL, 
ERAP-SA, ERAP-Tot and GAPDH, gene housekeeping used as a reference for assessing 
the increases. 
 
 
3.11 Antigen presentation pathway 
Antigen presentation pathway was analyzed in a PCR array including a set 
of optimized real-time PCR primers on 96-well plates (LONZA, Basel, 
Switzerland). This approach permits to monitor mRNA expression of 84 
genes involved in nearly all aspects of antigen processing and presentation 
following the procedures suggested by the manufacturer. The experiments 
were run on all of the subjects included in the study pooled into three 
distinct homo A, homo B and hetero AB groups. Thus, the results 
represents the mean value of the different targets analyzed in homo A, 
homo B and hetero AB groups. Furthermore, those targets showing marked 
differences between the three groups analyzed were retested by Real time 
PCR on each individual sample confirming the data obtained in the array. 
 
 
GAPDH 
For CGGATTTGGTCGTATTGGG 
Rev GCTTCCCGTTCTCAGCCTTG 
TAP1 
For GCTGCCCACCAATGTAGAGGA 
Rev GGCGAAGCCCAGAAGTTTAGG 
IFN 
For GGCGACAGTTCAGCCATCAC 
Rev TGTGGAGACCATCAAGGAAGACA 
ERAP2tot 
For TCCAAACCAGCGGAAACCC 
Rev CTGCTCCACAAGTCATCATTC 
ERAP2FL 
For CCCAAGATGACAAGTAACATGCTC 
Rev GGAAGCGCTCCTGTTGCAG 
ERAP2SA 
For GAGATCTGTGGAATAGCCTGACC 
Rev GGAAGCGCTCCTGTTGCAG 
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3.12 Cloning plasmid construction and transfection 
The cDNA of ERAP2 was PCR amplified using high fidelity polymerase 
(Pfu DNA Polymerase, Promega) from both hap A and hap B homozygous 
cell lines. To amplify the two isoforms of ERAP2, the following sequence of 
oligonucleotides were used: 
Forward:5’ATACgcgatcgccATGcatcatcatcatcatcatATGTTCCATTCTTCTGC
AATGG 3’ 
Reverse:5’CTTGgtttaaacTTAAGTATTAACCATTAGCCAAGTCCTCAGAGT
C 3’ 
The two products were checked by direct sequencing and cloned into Flexi 
Vectors (Promega, Madison, WI, USA). After purification, PCR products 
were digested with the restriction enzymes SgfI and PmeI and ligated with 
T4 DNA Ligase. The translation reaction was performed with pF3WG 
(BYDV) Flexi Vector and the protein products were analyzed in SDS 
plyacrylamide gels (Promega, Madison, WI, USA). 
3.13 Protein extraction  
As ERAP2 is a transmembrane protein, the Kit Mem-Per Eukaryotic 
Membrane Protein Extraction Reagent (Thermo Scientific) was used to 
separate membrane protein from cytosolic protein so as to enrich the 
protein fraction of interest. 10x106 of PBMCs were centrifuged at 850 for 2 
min. The pellet was washed with PBS and 150 µl of lysis solution was 
added for 10 min on ice. 450 µl of solubilizing membrane cell reagent plus a 
proteases inhibitor cocktail were then added for 30min on ice. Finally, 
supernatants were collected and stored in new tubes at -20 °C until use in a 
BCA assay (Pirce) for protein quantification. 
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3.14 Western Blot analyses 
Protein extracts from approximately 10x106 PBMCs were separated on a 
4–12% NuPage Bis-Tris gel (Invitrogen, Paisley, UK) at 120 V for 50 
minutes in 16 NuPage MES SDS Running Buffer (Invitrogen, Paisley, UK). 
After transfer to a nitrocellulose membrane, proteins were detected using a 
1:5,000 dilution of primary antibody [goat anti-ERAP2 polyclonal antibody 
(AF3830, R&D Systems, Minneapolis, MN, USA); anti-ß-actin monoclonal 
prepared in mouse (A5316, Sigma, Saint Louis, MO, USA)] and a 1:10,000 
dilution of secondary antibody conjugated with alkaline phosphatase [goat 
anti-mouse IgG (sc-2005; Santa Cruz Biotechnology) and anti-goat IgG 
(A4187; Sigma, Saint Louis, MO, USA)]. Proteins were then visualized by 
enzymatic reaction after treatment with Sigma fast BCIP/NBT for 5 minutes 
(B5556; Sigma, Saint Louis, MO, USA).  
3.15 Transfection  
HeLa cells (uterine cervix carcinoma-derived cells) were cultured in DMEM 
high glucose supplemented with 10% FBS, 100 U/mL penicillin/ 
streptomycin, 2 mM glutamine. The cells were transfected with vectors 
pcDNA3.1/CT-GFP-MOUSE ERAP2-FL and ERAP2-SA using 
Lipofectamine 2000 (Invitrogen). The cells were spread in 6-well plates at a 
confluence of 70%. 3 µg of plasmid DNA and 15 µl of lipofectamine were 
incubated separately for 5 minutes in 250 µl of OptiMEM medium. Cells 
were then incubated 20 minutes at room temperature and added to the 
plates. Immunofluorescence analysis of transfected cells was performed 24 
hours after transfection. 
3.16 Immunofluorescence 
The cells were incubated 2 h with the anti-HIS tag primary antibody 
(Chemicon International, Inc. Temecula, CA, USA) and anti-calreticulin as a 
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marker of the endoplasmic reticulum (Affinity BioReagents)( diluted 1:50 in 
PBS with BSA and saponin). Cells were subsequently washed in PBS and 
incubated with secondary antibodies Alexa Fluo 488 and 594 (Invitrogen 
Life Science, Carlsbad, CA, USA), diluted 1:500 in PBS with BSA and 
saponin. The nuclei were stained with 4 ', 6'-diamidino-2-phenylindole 
(DAPI, Sigma Aldrich) for 15 minutes at room temperature. The images 
were acquired using a Leica TCS SP2 AOBS confocal laser scanning with 
a 63x magnification and a resolution of 1024x1024 pixels. 
3.17 HLA expression on CD45+ cell surface 
Flow cytometric analysis was performed 5 days post in vitro HIV-1 infection 
staining 0,5x106 PBMCs for 15 minutes with fluorescent directly labeled 
surface antibodies: CD45pecy5 and HLA-ABC FITC (Beckman Coulter, CA, 
USA). Cells stained with the appropriate isotype-matched Ig were used as 
negative controls. After staining, cells were fixed in 1% paraformaldehyde 
(PFA, Sigma-Aldrich). HLA-ABC expression was evaluated as mean 
intensity fluorescence (MFI) on leukocytes gated by CD45+ cells. Analyses 
were carried out blindly with respect to genotypes. Cytometric analysis was 
performed on 200,000 CD45 events using a FC500 flow cytometer 
(Beckman-Coulter CA, USA). Green florescence from FITC (FL1) is 
collected through a 525-nm band pass filter and deep-red fluorescence 
from Cy5PE (FL4) was collected through a 670-nm band pass filter using 
linear amplifiers for forward and side scatter and logarithmic amplifiers for 
FL1 and FL4. Flow data were analyzed by first gating on the leukocyte 
population as defined by forward and side light scatters and then on CD45 
expression.  
3.18 Statistical analysis 
Statistical analyses were performed using SPSS Statistical Package for the 
Social Sciences (version 11; SPSS Inc., Chicago, Illinois, USA). 
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Differences between the groups were assessed using nonparametric 
analyses (Mann–Whitney U test). All P values are two-tailed. For meta-
analysis a random-effects model as implemented in PLINK (Purcell et al., 
2007) was applied. 
. 
  
CHAPTER 4. RESULTS AND 
DISCUSSION 
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4.1 Genetic association with HIV-1 infection susceptibility 
The haplotype A of ERAP2 was shown to have a higher frequency in a 
cohort of seronegative subjects who have been repeatedly exposed to HIV 
through unprotected heterosexual intercourses (Cagliani et al., 2010). To 
confirm this association we genotyped the rs2549782 variant that tags the 
two major ERAP2 haplotypes, with the G allele deﬁning hap A 
(rs2549782G[392Lys]-rs2248374A [canonical splice site]) and the T allele 
deﬁning hap B (rs2549782T[392Asn]rs2248374G[alternative splice site]) in 
a cohort of Spanish IDU-HESN and in age- and sex- matched HC. Thus, 
according to genotyping, participants were divided in Hap A/Hap A 
homozygotes (homo A), Hap B/Hap B homozygotes (homo B) or Hap 
A/Hap B heterozygotes (hetero AB). Results showed that the frequency of 
homo A was 26% and 14% in IDU-HESN and HC, respectively. The 
difference was statistically significant and the odds ratio for a recessive 
model with homo A being protected from HIV-1 infection is 0.49 (95% CI: 
0.24- 0.99, Fisher's exact P= 0.033) (Table 1a). To perform a meta-analysis 
we used data from a previously published study. As estimation of the effect 
of heterogeneity is inaccurate when few data sets are included in the meta-
analysis, we applied a random-effects model ( Kavvoura 2008 10 ) and 
obtained a p value of 7.6 x10-5 (OR= 0.41) (Table 4.1). These results 
confirm that the rs2549782 ERAP2 variant is associated with protection 
against HIV infection and show how this effect is independent of the route 
of exposure. 
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Association study in the Spanish cohort  Meta-analysis
a
 
Phenotype Genotype 
counts 
(GG/GT/TT) 
 Genotype 
counts 
(recessive 
model, 
GG/GT+TT) 
Fisher's p 
(recessive) 
OR (95% CI)  Het. p-
value
b
 
I
2 c
 pmeta
d
 ORmeta
e
 
IDU-HESN 27/46/31  27/77 
0.033 
0.49 
(0.24- 0.99)  
0.42 0 
7.6 
x10
5
 
0.41 
HC 19/75/36  19/111  
      
a 
Meta-analysis was performed using data from a previous study of Italian sexually-exposed HESN subjects
 
b
 P value from Cochran Q heterogeneity test 
c  
heterogeneity index 
d
 random-effects meta-analysis p value 
e
 Random-effects OR estimate 
 
 
Table 4.1. Association study and meta-analysis for rs2549782 in HESN 
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4.2 Co-segregation of HLA-B*57 with rs2549782 genotypes 
The protective effect of HLAB57, has been confirmed in different studies in 
which the authors highlighted the ability of HLAB57-restricted CTL to target 
multiple HIV peptides (Makadzange et al., 2006; Boutwell et al., 2009). To 
verify whether ERAP2 haplotype status interacts with HLA-B*57, we 
genotyped rs2549782 and performed a co-segregation analysis on PBMCs 
isolated from 68 Italian  sexually-exposed HESN and 187 HIV+ patients. 
Results showed that 32% of homo A HESN are also HLA-B*57 positive, 
compared to only 6% of non-homo A subjects (p=0.010), indicating that the 
HESN phenotype is associated with the co-presence of the HLA-B*57 allele 
and the homo A status at ERAP2, suggesting their synergy in protection 
from infection. The same situation is not observed among HIV+patients, as 
the percentage of homo A and non-homo A individuals carrying the HLA-
B*57 allele was similar (5% and 7%, respectively; p=0.73) (Tab. 4.2). 
 
Phenotype 
 
HLA-B*57 
status  
rs2549782 genotype 
 
p valuea 
    GG (homoA) GT or TT (non-
homoA) 
  
HESN  HLA-B*57+  6 3  0.011 
 
 HLA-B*57-  13 46  
 
       
 
HIV
+
  HLA-B*57+  5 9  0.14 
  HLA-B*57-  29 144   
        
 
Table 4.2. Co-segregation analysis of HLA-B*57 with rs2549782 genotypes in 
HESN and HIV
+
patients 
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4.3 ERAP2-FL, ERAP2-AS and ERAP2-Tot mRNA basal 
expression 
To further confirm these results, we enrolled 139 healthy controls and 
grouped them according to their ERAP2 genotype. The genotyping analysis 
of ERAP2 in these samples show that there were 35 homo A, 40 hetero AB 
and 64 homo B. Hap A and B were equally represented, reflecting the allele 
frequency reported for major human populations 
(www.hapmap.ncbi.nlm.nih.gov). On PBMCs isolated from subjects with 
different ERAP2 genotype we evaluated mRNA basal expression of 
ERAP2-FL, ERAP2-AS and ERAP2-TOT. 
As expected basal mRNA transcription level for ERAP2-FL was significantly 
higher in homo A compared to hetero AB cells (p=0.04). Unexpectedly, 
marginal levels of ERAP2-FL mRNA are also detected in homo B PBMCs, 
these levels however, were significantly lower compared to those observed 
either in homo A (p=0.00031) or in hetero AB (p=0.006) cells (Fig. 4.1a). 
Opposite results were obtained analysing ERAP2-AS mRNA. Thus, 
ERAP2-AS mRNA was found in homo B and, albeit in limited quantities, in 
hetero AB cells (p=0.0004), while it was completely absent in homo A 
PBMCs (Fig. 4.1b). 
Finally, high, intermediate and low levels of ERAP2-Tot expression were 
seen in homo A, hetero AB and homo B samples respectively (Fig. 4.1c). 
These differences were statistically significant (P<0.05 in both cases), 
suggesting that subjects with different ERAP2 genotype do express diverse 
quantities of ERAP2 that may qualitatively and or quantitatively affect the 
antigenic repertoire and consequently activating a diverse immunological 
response.  
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Figure 4.1. Basal mRNA expression of ERAP2-FL (a) ERAP2-AS (b) and ERAP2-Tot (c) in 
cells of subjects with homo A (black bars); hetero AB (grey bars); and homo B (white bars) 
ERAP2 genotype 
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4.4 mRNA expression of ERAP2-FL and ERAP2-AS in IFN-
stimulated PBMCs 
Since IFNis a potent stimulator of all genes directly involved in MHC class 
I antigen presentation, we investigated whether this cytokine affects the 
expression of ERAP2 variants.  
We first analysed the kinetic of ERAP2-FL mRNA-expression on PBMCs 
isolated from 10 healthy controls stimulated by IFN. TAP1 was evaluated 
as positive control. Thus, PBMCs were stimulated with two doses of IFN 
(10 ng/ml and 100ng/mL) for 3h, 24h, 48h and 72h. 
Results showed an increased expression of ERAP2-FL at 48h fold change 
(FC) 6 and a subsequent decrease at 72h after stimulation (FC 1) 
(Fig.4.2a). TAP1 mRNA expression mirrored ERAP2 trend (Fig 4.2b).In 
addition, since we did not observe any difference between the two doses of 
IFN, the lowest dose was used in the following experiments. 
After 48h of IFN-stimulation, we evaluated mRNA expression of ERAP2-
FL and ERAP2-AS on PBMCs isolated from 139 subjects divided according 
to their different ERAP2 genotype. As previously reported, following IFN 
stimulation we observed an increased ERAP2-FL-mRNA expression in 
homo A (FC 600) and hetero AB subjects (FC 400). These results were 
statistically significant, with a p value 0.05, in both subjects homo A and 
hetero AB compared with their unstimulated conditions (Fig.4.2c). Similarly, 
ERAP2-AS mRNA transcription level was augmented in homo B (FC 150) 
and hetero AB subjects (100) with a p-value < 0.05 (Fig 4.2d). 
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Figure4.2. mRNA expression of ERAP2-FL (a) and TAP 1 (b) in cells isolated from 10 HC 
and stimulated with 10 ng/ml (blue line); and with 100 ng/ml (red line) of IFNγ;at different 
time points. c & d mRNA expression of ERAP2-FL and ERAP2-AS in homo A hetero AB and 
homo B individuals in unstimulated (blue bars) and IFNγ-stimulated PBMCs (light blue bars). 
Results represents mean values ± SE.* p<0.05
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4.5 Susceptibility to HIV infection in subjects with different 
ERAP2 genotype 
To verify if the expression of a diverse variant of ERAP2 influences 
susceptibility to HIV-1 infection, PBMCs isolated from the same 139 HC 
cohort described above were in vitro infected with a R5 tropic HIV-1 strain. 
Five days after infection p24 levels were significantly lower in homo A 
compared to both homo B (p=0.036) and hetero AB samples (p=0.003) 
(Fig. 4.3a). These results are consistent with the previously suggested 
recessive model of HIV-1 protection conferred by Hap A, and with the 
genetic association analysis in the IDU-HESN cohort (Table 4.1). 
Furthermore, it is interesting to observe that the heterozygotes have not an 
intermediate response compared to the other groups but become infected 
as much as homo B indicating a dominant negative effect of haplotype B on 
haplotype A. 
Conversely, p24 levels in CD4+ T cell cultures isolated from 42 HC (7 homo 
A; 23 hetero AB; 12 homo B) were comparable in the three genotypic 
group, suggesting a role for CD8+ T cells in the regulation of this 
mechanism of resistance (Fig. 4.3b). 
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a 
                                             
 
b 
 
Figure 4.3. p24 concentration in PBMCs (a) and (b) CD4+ T cells of subjects with different 
ERAP2 diplotype after 5 days of HIV infection. Mean values and S.E. are shown. ¼p <0.05, 
¼p <0.005.
** 
** 
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4.6 Analyses of ERAP2-FL, IFNγ and TAP1 mRNA expression in 
PBMCs of individuals with different ERAP2 genotype  
Following 3 days of in vitro HIV infection, analyses of mRNA specific for 
genes (ERAP2-FL, TAP1, IFNγ) involved in the presentation of peptides by 
MHC class I molecules to CD8+ T cells showed a completely diverse trend 
in subjects with different ERAP2 genotype. Thus, a significantly higher 
transcription rate was observed for these three genes in homo A compared 
to both homo B and hetero AB cells (p< 0.05 for all comparisons) (Fig.4.4).  
Notably, ERAP2-FL (Fig.4.4a), TAP1 (Fig.4.4b) and IFNγ (4.4c) mRNA 
expression was inversely correlated to p24 concentration, suggesting a 
possible association between the expression of these genes and 
susceptibility to HIV infection, possibly secondarily to a higher efficacy of 
cell mediated immunity. 
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Figure 4.4. mRNA expression of endoplasmic reticulum aminopeptidase type 2 (ERAP2)-
full-length (a), transporter associated with antigen processing 1 (TAP1)(b) and interferon-g 
(c) after HIV-1 infection. ERAP2-FL, TAP1, and interferon- mRNA expression in PBMCs 
from homo A (black bars), hetero AB (grey bars) or homo B (white bars) ERAP2genotype 
participants after 3 days of HIV infection. Mean values and standard error are shown. * 
P<0.05, ** P<0.005. 
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4.7 Antigen processing and presentation pathway 
To determine whether the differences observed for ERAP2-FL, TAP1 and 
IFNexpressionin cells of individuals with different ERAP2 genotypes 
could be extended to other factors involved in the antigen processing and 
presentation pathway, we used a Real-time PCR array, which screens for 
the expression of 84 genes implicated in that process. 
Data obtained 3-days post in vitro HIV infection (Figure 4.5) showed a 
generalized and significant increase of a great number of the genes 
involved in the antigen processing and presentation pathway in homo A 
compared to both homo B and hetero AB cells. Notably, the 29 targets, 
which are expressed at a higher transcriptional rate in homo A, are involved 
in nearly all aspects of antigen processing and presentation, including: 
regulation and enhancement of class I and class II expression (ABCB9, 
B2M, CALR, CD74, CTSE, CTSL2, HSPA5, HSP90AB1, HFE, IRF2, IRF8, 
LGMN, HLA-A, HLA-B, HLA-G, HLA-DQB2, HLA-DRA, PML, RFXANK, 
TAPBP), the proteasome system (PSME2), costimulation of antigen 
presentation (CD40, CD46, ICOS, PRKCD, STAT1), lysosomal proteases 
(LGMN), antigen uptake by APC (CD209, CDC42), and aminopeptidases 
(NPEPPS). 
Thus, it is tempting to speculate that the presence of a wider or more stable 
peptide repertoire generated by ERAP2 homo A cells is capable to boost 
the antigen presentation machine resulting in a more protective response to 
the virus.  
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Figure 4.5.  Antigen processing and presentation pathway genes mRNA expression in cells of participants with homo A (black bars), hetero 
AB (grey bars) or homo B (white bars) ERAP2 genotype 3days after in-vitro HIV-infection. The expression of 84 genes involved in the antigen 
processing and presentation pathway was assessed by real-time quantitative RT-PCR and shown as fold-change expression from the 
uninfected sample. Only the targets showing different expression levels in the three groups are presented 
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4.8 Effect of ERAP2 variants on MHC class I expression 
Given that, experiments carried out by other research groups on cell lines 
showed that, silencing of ERAP2 causes a decreased expression of MHC 
class I molecules on the cellular surface and the transient knock-down of 
ERAP1 and ERAP2 was correlated to a reduced level of these molecules 
(Saveanu et al,.2005), we verified whether physiological down-regulation of 
endogenous ERAP2 had a similar outcome in haplotype B PBMCs. To this 
aim, we analysed HLA-A, B and C mean fluorescence intensities (MFI) on 
CD45+ leukocytes. Results showed that MHC class I (HLA-A, B, C) MFIs 
are significantly reduced in hetero AB and homo B compared to homo A 
cells both in basal condition and upon HIV-1 infection (p< 0.05 in all 
conditions) (Figure 4.6). These results demonstrate that the presence of the 
ERAP2 Hap B correlates with reduced levels of MHC class I expression on 
leukocyte surfaces, confirming a correlation between the presence of the 
homo A genotype and a stronger antigen presentation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. Human leukocyte antigen (HLA)-ABC mean ﬂuorescence intensities of CD45þ 
cells in homo A (black bars), hetero AB (grey bars) and homo B (white bars) participants. 
Mean values and standard error are shown. *P<0.05, **P<0.005.
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4.9 ERAP2 protein expression in PBMCs of individuals with 
different ERAP2 genotype  
To verify if the mRNA derived from the full-length and alternative spliced 
form of ERAP2 are both translated into functional proteins we performed a 
western blot analyses on PBMCs isolated from homo A, homo B and hetero 
AB individuals. Results showed that homo A as well as hetero AB PBMCs 
produce only full-length ERAP2 (120 kDa), while no detectable ERAP2 
protein was found in cells isolated from homo B subjects. Notably, the 
intensity of the full-length ERAP2 band in hetero AB subjects was around 
half of the one detected in homo A subjects. Conversely, the truncated 
ERAP2 protein (62 kDa) could not be detected in any of the analysed 
subjects, independently of their ERAP2 genotype. Recombinant ERAP2-AS 
and ERAP2-FL forms are used as positive controls (Figure 4.7). These 
data corroborate the assumption that ERAP2-AS mRNA undergoes a non-
sense-mediated decay (Andres at al., 2010), but do not explain why hetero 
AB subjects display the same phenotype as homo B. 
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Figure 4.7.  PBMCs isolated from two participants representative of each ERAP2 diplotype 
(homo A, hetero AB and homo B) were tested for protein using primary antibodies speciﬁc to 
(a) ERAP2 (goat polyclonal) and (b) b-actin. Recombinant positive controls for the full-length 
positive (FLþ) and alternative spliced positive (ASþ) form of ERAP2 were also loaded. 
 
4.10 mRNA expression of ERAP2-FL and ERAP2-AS in 
gentamicin stimulated PBMCs 
To verify whether the mRNA derived from the transcription of the non-
synonym mutation Asp392Lys is degraded by intracellular mechanisms, as 
previously suggested by other authors (Andres et al., 2010), we analyzed 
the effect of pharmacological inhibition of non-sense-mediated decay 
(NMD). In this respect, PBMCs from 12 HC with different ERAP2 genotypes 
were isolated and treated with 300 µg of gentamicin for 20h, ERAP2-AS 
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and ERAP2 FL (positive control) mRNA expression are analyzed with real 
time PCR. Results showed that mRNA of both ERAP2-FL(Figure 4.8a) and 
ERAP2-AS (Figure 4.8b) is not increased after antibiotic treatment, thus 
confirming that ERAP2-AS is not degraded by the NDM pathway.  
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Figure 4.8. Effect of NMD inhibitor on ERAP2-FL (a) and ERAP2-AS (b) mRNA transcript 
level. GAPDH was used as a reference gene.Mean values±standard errors are shown 
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4.11 ERAP2-FL and ERAP-AS localization in endoplasmic 
reticulum 
To identify the localization of ERAP2-FL and ERAP2-AS, an 
immunofluorescence assay is performed on HeLa cells transfected with the 
pcDNA3.1/CT-GFP-MOUSE vector, which encodes for both ERAP2 
variants. Confocal microscopy showed that anti-histidine antibody, that tags 
both ERAP2 variants, co-localize with calreticulin antibody (Figure 4.10). 
Data suggest that whether ERAP2-AS mRNA might be translated in its 
functional product, it localizes at the level of the endoplasmic reticulum 
where it could exert its biological function. 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10. Confocal microscopy of ERAP-FL and ERAP2-AS (green) in endoplasmic 
reticulum (red). Merge of ERAP2-AS and calreticulin (yellow) 
  
CHAPTER 5. CONCLUSIONS 
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The important biological functions of ERAP1 and ERAP2, in modulating the 
adaptive immune response are confirmed in recent studies. In particular, 
the variant that tags Hap A (rs2549782-G) in ERAP2 was shown to protect 
from sexually-transmitted HIV-1 infection (Cagliani et al., 2010). This initial 
observation is based on the analysis of a relatively small cohort of Italian 
HESN. Data herein replicate the association between the ERAP2 
polymorphism and HIV-1 protection in an independent cohort of subjects 
with different geographic origin and a diverse infection exposure route. 
Meta-analysis of the results obtained in the two cohorts provided strong 
support to the association between diplotype status at ERAP2 and natural 
resistance to HIV-1 infection, suggesting that the protection from infection is 
independent on the route of exposure. 
To confirm their role in susceptibility to infection, we analyzed the PBMCs 
from homo A subjects under HIV-1 infection, allow lower viral replication 
compared to cells derived from both hetero AB and homo B subjects. 
Conversely, p24 levels in CD4+ T cell cultures are comparable in the three 
genotypic groups, indicating an involvement of CD8+ T lymphocytes in the 
regulation of this mechanism of resistance.  
This effect may at least partially be mediated by different ERAP2 
expression levels in subjects with diverse ERAP2 genotype. In fact, results 
herein indicate that both in basal condition and following in vitro HIV-1 
infection the transcript level for ERAP2-FL and ERAP2-Tot was significantly 
higher in homo A compared to hetero AB and barely detectable in homo B 
cells. These data are in line with previous observations and with western 
blot results, suggesting that ERAP2 diplotype status determines the 
abundance of the full-length protein product of ERAP2, which, in turn, might 
shape the antigen repertoire available for CD8+ T cell clone stimulation. 
Moreover, we were unable to detect any signal for the truncated protein. 
These data corroborate the assumption that ERAP2-AS mRNA undergoes 
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a non-sense-mediated decay, but we have shown that this mechanism 
does not affect the mRNA of ERAP2-AS. There are several possible 
explanations to understand why we were unable to detect the ERAP2-AS 
form. First, the amount of truncated protein might be under the sensitivity 
threshold of the technique, but could still exert a dominant negative effect. 
Second, the amount of full-length ERAP2 protein might be rate-limiting for 
efficient antigen presentation, so that a decrease in the overall available 
protein is sufficient to produce an immunologic response to HIV-1 infection 
that is scarcely protective. Third, alterations in ERAP2 availability might 
affect the stoichiometry of ERAP1/ERAP2 hetero-dimers formation. Indeed, 
the two aminopeptidases are known to physically interact, although the 
precise fraction of ERAP1 and ERAP2 which is engaged in complex 
formation is unknown (Saveanu,L. 2005). Lower levels of ERAP2 protein 
might thus alter the relative abundance of homo- and hetero-dimers and, as 
a consequence, the final repertoire of MHC I available cargos. This in turn 
might be relevant to the specificity of CD8+ T cells, as suggested with 
ERAAP-deficient mice (Hammer 2007; Hammer 2006; Yan,J. 2006; York 
2006; Firat 2007). 
Confirming the assumptions and the results previously obtained we 
demonstrate that reduction of ERAP2-FL levels results in a quantitative 
diminution of MHC class I expression both in uninfected and HIV-1 infected 
cell cultures when homo A are compared both to homo B and hetero AB 
CD45+ cells. Notably, results also demonstrated that, following HIV-1 
infection, not only ERAP2-FL but also a number of genes directly involved 
in the antigen processing and presentation pathway are expressed at a 
higher levels in homo A compared to both homo B and hetero AB cells. The 
genes whose mRNA is upregulated in homo A cells are implicated in 
almost all phases of antigen processing and presentation, including the 
regulation and enhancement of class I and class II expression (TAP1, 
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ABCB9, B2M, CALR, CD74, CTSE, CTSL2, HSPA5, HSP90AB1, HFE, 
IRF2, IRF8, LGMN, HLA-A, HLA-B, HLA-G, HLA-DQB2, HLA-DRA, PML, 
RFXANK, TAPBP), the proteasome system (PSME2), antigen presentation 
costimulation (CD40, CD46, ICOS, PRKCD, STAT1), lysosomal proteases 
(LGMN), as well as antigen uptake by antigen presenting cells (CD209, 
CDC42) and aminopeptidases (NPEPPS). It is possible to speculate that in 
the presence of a wider or more stable peptide repertoire generated by 
ERAP2 homo A cells all the factors involved in the presentation of the 
antigen are boosted, contributing to the activation of an optimal immune 
response. 
Indeed, the role of ERAP1 and ERAP2 in antigen processing and 
presentation suggests that variants in these genes might also interact with 
specific HLA class I alleles to modulate distinct phenotypes. Therefore, the 
role of ERAP1 and ERAP2 in antigen processing and presentation 
suggests that variants in these genes might also interact with specific HLA 
class I alleles to modulate distinct phenotypes. 
Data herein indicate that, in HESN, the HLA-B*57 allele is much more 
common than expected among homo A subjects, suggesting synergy in 
protecting from infection. Whether additional HLA alleles interact with 
ERAP2 genotypes remains to be evaluated, but is a likely possibility as 
multiple alleles, as well as specific amino acid residues in HLA-B and HLA-
C, are known to control HIV viral load. 
To summarize, ERAP2 diplotype status is associated with resistance to HIV 
infection; this effect is probably secondary to the modulation of the antigen 
processing/presenting machinery, resulting in quantitative and possibly 
qualitative changes in MHC class I complexes on target cells.  
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